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ABSTRACT

THE EFFECT OF L-DOPA AND NATURAL PRODUCTS ON AGE-RELATED
MOTOR DEFICITS AND DOPAMINERGIC CELL SURVIVAL

By
Erika Nicole Allen
December 2013

Dissertation supervised by Jane E. Cavanaugh, Ph.D
With age, there is a loss of motor coordination leading to an increase in
falls. Currently, there are limited therapeutic regimens for age-related motor deficits.
However, L-DOPA is used for motor dysfunction in Parkinson’s disease (PD). Therefore,
we investigated the effect of L-DOPA on motor deficits in young (2 mo) and old (20 mo)
mice. We found that L-DOPA reversed age-related motor decline.
Chronic

L-DOPA

use produces involuntary movements or dyskinesias.

Interestingly, natural foods, such as wild blueberries (WBB), and isolated compounds,
such as resveratrol and pinostilbene, have beneficial effects on several physiological
processes with few side effects. Therefore, to examine the effect of these natural products
on motor function, mice (2, 10 and 20 mo) were fed resveratrol, pinostilbene, or WBB
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containing diet. The age-related loss of motor coordination was attenuated in animals fed
resveratrol and WBB diets, while pinostilbene diet increased spontaneous activity.
To investigate the mechanism that may underlie this reversal of motor deficits,
striatal dopamine (DA) and DA metabolite levels and the number of DA neurons in the
substantia nigra were examined. None of these parameters changed with age or in
animals fed resveratrol or pinostilbene diets. However, WBB increased the number of
DA neurons in the substantia nigra in aged animals.
To further investigate the mechanism that may underlie the alleviation of motor
deficits, the effects of resveratrol or pinostilbene on oxidative stress-induced cell death
and the expression and activation of ERK1/2 and ERK5, kinases known to protect from
oxidative stress, were examined in DA cells. Resveratrol and pinostilbene decreased DAinduced cell death and activated ERK1/2, but not ERK5. Pretreatment with U0126, an
inhibitor of the ERK1/2 pathways, blocked the resveratrol- and pinostilbene-mediated
neuroprotection.
Together, these data suggest that resveratrol, pinostilbene, and/or WBB may
decrease age-related motor deficits by protecting DA neurons from oxidative stress via
activation of the ERK1/2 pathway. As the use of natural supplements is on the rise, it is
important to understand the therapeutic and physiological effects of these compounds.
Moreover, this research may lead to the use of these natural compounds as novel
therapies for age-related motor deficits.
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1. INTRODUCTION
1.1 Aging and society
The percentage of people aged 65 years and older has increased from 12.4% of
the United States (US) population in 2000 to 13.0% of the US population in 2010 with a
projected increase to 20.2% by 2050 (US Administration on Aging, 2011). Moreover, the
number of people aged 65 and older is projected to more than double from 41.4 million in
2011 to 92 million in 2060 (US Administration on Aging, 2011). The significance of this
increase in the aged population, along with a predicted deficit in Medicare and Social
Security by 2016 (GAO, 2002), is that the incidence of age-related injuries and diseases
will rise leading to a concomitant increase in health care costs.
Due to an increase in injuries, illness, and disease, the elderly population over 65
years of age averages more visits to doctor’s offices and longer, more frequent hospital
stays than any other age group. This is problematic because older adults averaged out-ofpocket health care expenditures of $4,769 in 2011, an increase of 46% since 2000 (US
Administration on Aging, 2011). Therefore, with an increase in the aging population and
a concurrent decrease in the amount of funding for insurance, there is a concern about
quality of life for the aging population.
1.2 Aging and motor coordination
Aging is associated with a decline in motor coordination, an increase in cognitive
deficits, chronic illnesses, and diseases, such as Parkinson’s disease (PD) or Alzheimer’s
disease (AD; Fozard et al., 1994; Prettyman, 1998; Hof and Mobbs, 2001). Of these
1

ailments, a loss in motor coordination becomes increasingly debilitating with age because
the risk of injury from falling may lead to long-term disability, pain, and untimely death
(Allum et al., 2002). For example, falls are the leading cause of unintentional injury and
injury-related death in the elderly, and this increase in falls leads to an increase in the risk
of fractures, with 20% of falls requiring admission to the hospital (Uusi-Rasi et al., 2012).
Currently, this age-related decline in motor skills is not treated clinically unless
the loss of motor coordination is linked with diseases, such as PD or AD. When linked
with PD, symptoms of motor deficits such as postural tremor, muscular rigidity, postural
abnormalities, bradykinesia, and impaired balance are treated with drugs that increase the
actions of the neurotransmitter dopamine (DA). The DA neuronal system and its role in
motor function are reviewed below.
1.3 The dopamine system
1.3.1 Dopamine
Dopamine (DA) is a catecholamine that until the 1950’s was only known as a
precursor for the neurotransmitter norepinephrine (NE; Carlsson, 1957; 1958; 1959).
Currently, DA neurotransmission is known to play a role in regulating voluntary
movement, motor coordination (Pijnenburg and Van Rossum, 1973; Jackson et al., 1975;
Costall and Naylor, 1975; Costall et al., 1976), and higher cognitive functions, such as
learning and memory (Ploeger et al., 1991; Cools et al., 1993; Coccurello et al., 2000;
Mele et al., 2004). However, elucidation of specific signaling pathways regulated by DA
is challenging because DA modulates many cellular proteins, such as kinases,
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phosphatases, transcription factors, ion channels, and membrane receptors (Tritsch et al.,
2012).
DA is synthesized from the amino acid tyrosine. Tyrosine is converted to
levodopa (L-DOPA) by tyrosine hydroxylase (TH), the rate-limiting enzyme in DA
synthesis. L-DOPA is then converted into DA by aromatic L-amino acid decarboxylase.
DA is then packaged into vesicles and stored until a stimulus prompts release from the
presynaptic neuron. Once released into the synaptic cleft, DA can be metabolized by
catechol-O-methyltransferase (COMT), recycled into the presynaptic neuron by the
dopamine transporter (DAT), or act on pre- or postsynaptic receptors.
DA mediates its actions by interacting with a group of G-protein coupled
receptors (GPCRs) termed DA receptors 1 through 5 (D1-D5). D1 and D5 receptors act in
a similar manner and are considered D1-like receptors. Similarly, D3, and D4 act in
similar manner to D2 receptors and are therefore considered D2-like receptors. The
binding of DA to D1-like receptors increases adenylyl cyclase (AC) activity, which leads
to the production of cyclic adenosine monophosphate (cAMP) and the activation of
protein kinase A (PKA). In contrast to D1-like receptors, when activated, D2-like
receptors inhibit AC to limit PKA activation. Research has indicated that the motor
symptoms associated with PD, and possibly aging, are linked to a decrease in striatal D2
and D3 receptors (Joyce, 2001).
Dopamine cell bodies are located in the midbrain, specifically the substantia nigra
(SN) and ventral tegmental area (VTA). These cell bodies have projections that lead to
other parts of the brain, such as the cortex and other parts of the midbrain (striatum; Fig.
3

1). DA cells bodies and the projections have been grouped into three different tracts:
mesocortical, mesolimbic, and nigrostriatal (Fig. 1). The mesolimbic and mesocortical
tracts are important for reward, learning, and memory (van Domburg and ten Donkelaar,
1991). This study will focus on the nigrostriatal tract, which mediates motor coordination
and behaviors (van Domburg and ten Donkelaar, 1991).
1.3.2 Basal Ganglia
The basal ganglia are a collection of nuclei involved in directed movement,
planning and execution of goal-directed movement. The caudaute, putamen, and nucleus
accumbens nuclei in the basal ganglia process information received from the central
nervous system, particularly the cortex. Within the basal ganglia are groups of
dopaminergic, γ-aminobutyric acid (GABA)-ergic, norepinephrine (NE) and serotonin (5HT) neurons. GABA neurons are not only in the basal ganglia but project to the
substantia nigra to help regulate release of other neurotransmitters (Sian et al., 1999).
Interactions between neurons in the basal ganglia, more specifically the striatum, and the
substantia

nigra

help

to

regulate
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voluntary

movement.

Figure 1. Dopamine system in the brain.
Dopamine cell bodies originate in the substantia nigra and project to the mesocortical,
mesolimbic, and nigrostriatal tracts.
Image: NIDA; http://www.drugabuse.gov/publications/addiction-science/why-dopeople-abuse-drugs/brain-pathways-are-affected-by-drugs-abuse
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1.3.3 Substantia Nigra
DA cell bodies originate in the substantia nigra (SN) and project to the striatum in
the midbrain. This DA system, known as the nigrostriatal dopamine tract, is one of the
major control centers of motor coordination in the brain, and dopaminergic cell death in
the SN leads to a loss of motor coordination. With age, there is approximately a 5% loss
of neurons in this region per decade (Gao et al., 2013). However, depending on disease
state and species examined, this loss of DA neurons with age is controversial. For
example, some groups have noted a significant loss of DA neurons with age (McGeer et
al., 1977; Fearnley and Lees, 1991), while other groups have not observed an age-related
loss of DA neurons (Pakkenberg et al., 1991; Muthane et al., 1998) in elderly people.
Therefore, a connection between an age-related loss of DA neurons from the SN and
motor deficits is not universally supported by the literature. In contrast, it is widely
supported that PD patients show a loss of DA neurons in the SN leading to the motor
symptoms seen with this disease.
The DA neurons of the SN are particularly susceptible to oxidative stress and
inflammation, both of which are known to increase with age (Jenner and Olanow, 1996;
Joseph et al., 2000). There have been many reasons proposed as to why this occurs. One
reason may be that with aging there is an increased expression of pro-oxidative and
proinflammatory states in the nigra of aged animals, such as NADPH oxidase complex,
and an increase in inflammatory cytokines, IL-1β and TNF-α (Labandeira-Garcia et al.,
2011; Viller-Cheda et al., 2012). An increase in inflammation that is mediated by IL-1β
has been shown to increase the susceptibility of DA neurons to degredation (Koprich et
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al., 2008). Other studies, in both humans and rodents, have shown that SN neurons are
sensitive to neuroinflammation (Viller-Cheda et al., 2012) and toxicity related to iron
metabolism (Zecca et al., 2004) with age. Therefore, an imbalance in the homeostatic
environment of the substantia nigra may lead to a loss of DA neurons with age.
1.3.4 Striatum
The striatum is located in the midbrain and is part of the basal ganglia. The
striatum is broken into two subdivision, dorsal striatum that contains most of the caudate
and putamen, and ventral striatum, which contains the nucleus accumbens, ventromedial
parts of the caudate and putamen, as well as part of the olfactory tubercle. There are
multiple types of neurons contained in the striatum, including GABAergic and
cholinergic neurons (Ferre et al., 1997). GABAergic neurons make up 90-95% of the
neurons in the striatum (Ferre et al., 1997). DA signaling in the striatum, via complicated
connections with GABAergic interneurons and the rest of the basal ganglia plays a large
role in the control of voluntary movements and, thereby, motor coordination. To this end,
a loss of D2-like receptors in the striatum has been linked to motor decline seen in the
elderly (Kaasinen et al., 2000). However, as treatments for motor deficits are limited to
those that occur with a neurodegenerative disease, such as PD, there is a need for a
treatment for motor deficits that occur with normal, non-diseased aging.
1.4 Dopamine system in vitro
Cell culture models have been shown to be important tools for the analysis of
specific signaling pathways. To study cell signaling in DA neurons, primary cultures of
mesencephalic DA neurons are the model, which most closely mimics the in vivo
7

environment. However, these cultures contain GABA neurons, glia cells, and DA
neurons (Prochiantz et al., 1979, O’Malley et al., 1992) making it difficult to isolate the
signaling occurring only in the DA neurons. These cultures are also difficult to maintain
and give variable results depending on the DA neuronal content of each culture.
Therefore, a cell-line model of DA neurons, such as SH-SY5Y cells is widely utilized
(reviewed by Xie et al., 2010). SH-SY5Y cells are a dopaminergic-like cell model, which
were derived from a neuroblastoma. These cells express TH and DAT and exhibit
dopamine-ß-hydroxylase activity (Xie et al., 2010).
1.5 Treatment of motor deficits
Motor deficits that are associated with a disease, such as PD or AD, are most
often treated with L-3,4-dihydroxyphenylalanine (L-DOPA). This treatment was first used
following the discovery that striatal DA levels are decreased in PD patients as compared
to age-matched individuals (Hornykiewicz, 1966).

L-DOPA

is administered in

conjunction with a peripheral inhibitor of L-aromatic amino acid decarboxylase (AADC;
carbidopa), which blocks peripheral metabolism of L-DOPA. DA is not able to cross the
blood brain barrier (Pardridge, 2003). Therefore, the use of an AADC inhibitor improves
the efficacy of L-DOPA by allowing it to penetrate the brain before it is metabolized to
DA. Once in the brain, L-DOPA increases the synthesis and release of DA in the SN and
striatum, respectively (Rinne et al., 1971; Lloyd et al., 1975; Navailles et al., 2013).
In stroke patients, treatment with L-DOPA improved the function of affected
limbs (Rosser et al., 2008). Additionally, Floel and colleagues (2008) showed that
treatment with L-DOPA improved fine motor hand function in elderly patients. However,
8

there are limited clinical studies with L-DOPA as a treatment for conditions other than
PD.
1.6 Behavioral tests for motor function
1.6.1 Challenge beam task
The challenge beam test was developed as a modification of traditional beam tests
to provide a more sensitive measurement of skilled walking and motor coordination
(Fleming et al., 2004) and is used to measure time, steps, and errors while crossing the
beam towards the home cage. These parameters have been shown to be reliable
measurements of sensorimotor coordination (Ogawa et al., 1985; Goldberg et al., 2003;
Fleming et al., 2005). Mice are trained to traverse an elevated beam (4 segments, 25 cm
long by 3.5 cm at the widest segment, narrowing to 0.5 cm in 1 cm increments) and enter
their home cage on 2 separate days 24 hours apart. One week after training, wire mesh
with 1 cm2 openings is placed over the beam segments and the animals are videotaped
and timed during their traversals. Videotapes are then viewed and rated in slow motion
for the number of steps, time to cross, and errors by an investigator blinded to the
treatment group.
1.6.2 Spontaneous activity test
The cylinder test measures spontaneous activities through the examination of
movements that may are indicative of exploration, such as forelimb and hind-limb steps,
rears, and grooming. Mice will display exploratory behaviors in the cylinder by rearing
and placing their forelimbs on the wall of the cylinder (Schallert et al., 2000). This test
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has been used by others to show changes in forelimb and hind-limb movement and
rearing activity in mice and rats (Fleming et al., 2004; Kumar et al., 2009; Glajch et al.,
2012).
For these experiments, a small, transparent, Plexiglas cylinder (height 15.5 cm,
diameter 12.7 cm) is placed on a piece of glass that was elevated by four pedestals (6 in).
A mirror is placed underneath the glass and angled towards the video camera so that the
mice could be viewed from below. Animals are videotaped in the cylinder for 3 min and
videos analyzed for forelimb steps, hind-limb steps, rears, and time spent grooming by an
investigator blinded to the treatments. A step is counted when the animal moves both
paws across the glass and a rear is considered as a vertical movement with both front
paws leaving the glass floor.
1.6.3 Rotarod
The Rotarod machine consists of a rotating drum that a mouse can be placed on
and is expected to remain on the rod as it turns. These machines can be controlled to
increase the speed at which the mouse must walk in order to remain on the rod.
1.6.4 Gait walking
A gait analysis system, such as Catwalk 7.1 (Noldus IT, the Netherlands), can be
used to analyze gait parameters, such as walking speed, stride length, standing time,
swing length of limbs (Abada et al., 2013). A Catwalk system consists of an enclosed
walkway with a glass plate and a speed video recording camera. Gait performance was
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assessed and recorded using the catwalk analysis software. Rodents are habituated to the
walkway on the first day and the following day the runs are recorded by the software.
1.6.5 Balance beam
The balance beam is similar to the challenging beam; however there is not a mesh
grid that is placed on the beam. Mice are expected to traverse a narrow beam to their
home cage. The mice are then assessed for time it takes to traverse the beam and paw
slips (Luong et al., 2011).
1.7 L-DOPA, Parkinson’s disease, and dyskinesias
Motor symptoms associated with PD include bradykinesia, resting tremor,
rigidity, and postural instability. The appearance of these motor symptoms is thought to
evolve from the progressive degeneration of DA neurons in the SN that give rise to the
nigrostriatal tract (Hof and Mobbs, 2001). However, degeneration is advanced (50% of
SN neurons and 70% of striatal DA projections) by the time these symptoms manifest
(Joyce and Millan, 2007). Although L-DOPA is the most common treatment for motor
symptoms associated with PD, it has been shown to have what is considered a “wearingoff” phenomenon, which leads to L-DOPA-induced dyskinesias, or abnormal involuntary
movements, in a majority of PD patients that are on this therapy for a few years (Ahlskog
and Muenter, 2001; Mazzella et al., 2005). Once these dyskinesias have developed, they
are irreversible, even with cessation of L-DOPA treatment (Iderberg et al., 2012).
The cause of L-DOPA induced dyskinesias is unknown. One hypothesis is that LDOPA-induced dyskinesias develop due to the dosing regimen and mode of
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administration of L-DOPA, which do not allow for consistent levels of DA to be sustained
in the striatum (Smith et al., 2005; Cenci, 2007). Other studies suggest that L-DOPA, and
its product DA, are toxic to dopaminergic cells. The toxicity of L-DOPA and/or DA is
thought to occur due to the oxidation of DA into free radicals, quinones, hydrogen
peroxide, and lipid peroxides (Mytilineou et al., 1993; Hastings et al., 1996).
1.8 Oxidative stress and aging
Normal cellular metabolism generates reactive oxygen species (ROS), such as
superoxide (O2-), hydrogen peroxide (H2O2), and hydroxyl radicals (OH-). Cells have
natural defense mechanisms against ROS, such as glutathione (GSH), catalase, and
superoxide dismutase (SOD; Long, 1999). With age, increases in the rate of production of
ROS (Harman, 1992; Ames et al., 1993; Joseph et al., 1996), decreases in GSH and SOD
levels (Mo et al., 1995; Papadopoulos et al., 1998; Sasaki et al., 2001), and an increased
sensitivity of neurons to ROS (Ovadia et al., 1995; Desai et al., 1996; Ling et al., 2000;
Stadtman, 2001) have been reported. In addition to an increase in reactive oxygen species
(ROS), increases in reactive nitrogen species (RNS) have also been noted with age
(Ladiges et al., 2010).
High levels of ROS and RNS lead to neuronal death (Farooqui and Farooqui,
2008). Specifically, dopaminergic cell death has been shown to occur concomitantly with
an increase in levels of oxidative stress indicators (i.e., protein oxidation and lipid
peroxidation) in the ventral midbrain (Lopez-Real et al., 2005; Munoz et al., 2006; Rey et
al., 2007). Therefore, antioxidant compounds may protect neurons from oxidative stressmediated toxicity leading to a preservation of motor function with age.
12

1.9 Natural products as antioxidants
Antioxidant compounds isolated from natural resources are available as
supplements in pharmacies throughout the US and, therefore, their use by the general
public is on the rise (Das et al., 2012; Chauhan et al., 2013). As the idea of using a natural
compound is attractive to many, one of the goals of the current study was to examine the
effect of natural compounds on motor function in an aging animal model.
While there are several known natural antioxidants, this study focused on isolated
compounds derived from nuts and berries, resveratrol and pinostilbene, an analog of
resveratrol. Additionally, we chose wild blueberry powder as an example of a whole fruit
that has been shown to have antioxidant properties. The following sections provide a
review of these compounds.
1.9.1 Resveratrol
Resveratrol (3, 4’, 5-trihydroxystilbene) is a polyphenol found in plants and fruits,
such as grapes, mulberries, and peanuts (Baur et al., 2006). It is produced in response to
pathogen exposure, such as fungal infection or UV irradiation, and when plants are
stressed (Chao et al., 2010). Therefore, grapes that are grown in a warm, moldy, Southern
climate have significantly higher levels of resveratrol in their skins than grapes grown in
milder climates (Goldberg et al., 1994; Kolouchova et al., 2004; Lekli et al., 2010).
Isolated resveratrol has antioxidant (Olas, 2001; Chao et al., 2010), antibacterial
(Zhong et al., 2012; Nawrocki et al., 2013), anti-inflammatory (Donnelly et al., 2004; Das
et al., 2006), and anticancer properties (Nakagawa et al., 2001; Jang et al, 2001; Wang et
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al., 2010) in vivo and in vitro. Moreover, resveratrol increases the lifespan of yeast,
nematodes, Drosophila melanogaster, and mice on a high-fat diet (Baur and Sinclair,
2006; Baur et al., 2006).
1.9.2 Resveratrol analogs: Pinostilbene
Resveratrol has been shown to have poor bioavailability, in animal, human, and
cellular studies (Andlauer et al., 2000; Soleas et al., 2001). The poor bioavailability of
resveratrol is attributed to its rapid metabolism into glucuronides and sulfate conjugates
within 15 minutes of absorption (Marier et al., 2002; Goldberg et al., 2003). Therefore,
researchers have isolated or synthesized analogues of resveratrol, which may have less
absorption issues and more potent effects in natural foods than resveratrol due to
increased lipophilicity (Table 1). Figure 2 shows resveratrol and 8 analogs of resveratrol
that have been synthesized in the laboratory of our collaborator, Dr. Agnes Rimando
(Joseph et al., 2008). Chemical modifications to resveratrol, including methoxylation,
have been made to increase its bioavailability (Wilson et al., 2008), and thereby its
distribution throughout the body. One analog, pinostilbene (3,4'-dihydroxy-5methoxystilbene), has a substitution of methoxy in place of the hydroxyl group on the 5
position of resveratrol. Methoxylated stilbenes, such as pinostilbene, are metabolized
more slowly than hydroxylated stilbenes and, thereby, may have increased bioactivity
(Wilson et al., 2008). The methoxylated group may also increase lipophilicity of the
molecule, thereby increasing the permeation into cells and the brain. For example, Chao
and colleagues (2010) found that pinostilbene penetrated into SH-SY5Y cells more
effectively than resveratrol.
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Source

Resveratrol concentration

100% Natural peanut butter

0.65µg/g

Blueberries

32ng/g

Boiled peanuts

5.1µg/g

Cranberry raw juice

0.2mg/L

Dry grape skin

24.06µg/g

Grapes

0.16‐3.54µg/g

Red wine blend

20.33µM; 0.1‐14.3mg/L

Concord grape juice

1.56nmol/g

Pistachios

0.09‐1.67µg/g

White grape juice

0.05mg/L

White wines

<0.1‐2.1mg/L

Table 1. Amount of resveratrol in foods and beverages
Adapted from: S. Mukherjee et al., 2010. Dose-dependency of resveratrol in
providing health benefits. Dose-Response. 8: 478-500 and Wang et al., 2002.An LCMS method for analyzing total resveratrol in grape juice, cranberry juice, and in wine.
Journal of Agricultural and Food Chemistry. 50: 431-435.
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Figure 2. Structures of resveratrol and eight analogs.
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1.9.3 Whole natural products: Wild Blueberries
Natural products are a fantastic resource for the discovery of new compounds and
potential new therapeutics. A number of plants and foods have been shown to have
beneficial effects on cardiovascular health, cognition, inflammation, stroke, cancer, and
neuronal health. These foods contain compounds, such as anthocyanins and polyphenols,
have been shown to reduce cancer risk and improve neuronal survival (Prior et al., 2008).
Most of these natural products are available in our everyday diet in foods such as
walnuts, spinach, strawberries, grapes, peanuts, and wild blueberries. Of these, wild
blueberries are an excellent source of antioxidants and have the highest antioxidant
capacity per serving when compared to more than 20 other fruits (oxygen radical
absorbance capacity (ORAC) of Selected Foods, May 2010).
Wild blueberries are found growing in glacial soil, Northeastern United States,
and Canada. Wild blueberries are dissimilar to cultivated blueberries in that they are
smaller, darker in color. The dark skin of wild blueberries is an indication of the amount
of anthocyanins in their skins, which are observed as a dark purple/blue color (Prior et al.,
2008). Cultivated berries have more pulp and less skin as a percentage of the volume of
the blueberry, which decreases the antioxidant properties. Moreover, wild blueberries are
genetically diverse and offer a wide variety of protective properties, while cultivated
berries offer a limited spectrum of antioxidants due to the narrow genetic profile.
However, the question remains that when compounds are isolated from their natural
environments will they be as effective as they are in their natural state? Joseph and
colleagues (2010) showed that isolated compounds from wild blueberries, including
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anthocyanins, proanthocyanins, chlorogenic acid, and low and high molecular weight
proanthocyanins, were less effective at protecting primary hippocampal neurons from
oxidative stress than wild blueberry powder itself. Together these data suggest that
synergistic activity between the compounds may be necessary for full beneficial effects to
occur.
1.10 In vitro studies with natural products
1.10.1 Resveratrol in vitro
Resveratrol has been shown to decrease the release of inflammatory cytokines
(Tome-Carneiro et al., 2013; Zaky et al., 2013), improve neuronal cell survival following
antioxidant exposure (Peritore et al., 2012; Wu et al., 2012; Zhang et al., 2012), and
decrease cancer cell proliferation in vitro (Rigolio et al., 2005; Yin et al., 2013). For
example, in a cell culture model of prostate cancer, resveratrol was shown to decrease
cell proliferation, possibly by arresting these cells at the G1/S phase through the
induction of cyclin dependent kinase inhibitor 1A and B (Wang et al., 2010). Resveratrol
administration has also been shown to exhibit neuroprotective properties, possibly
through direct radical scavenging or through the induction of antioxidant pathways.
Resveratrol-mediated induction of heme oxygenase-1, an enzyme that catabolizes heme
to the antioxidant biliverdin (Zheng et al., 2010), has been shown to decrease oxidative
stress and, subsequently, cell death in primary neuronal cultures and smooth muscle cells
(Zhuang et al., 2003; Juan et al., 2005). In SH-SY5Y cells, Wu and colleagues (2011)
showed that resveratrol protected from rotenone-induced apoptosis by activating
adenosine monophosphate-activated protein kinase/sirtuin-1 (AMPK/SIRT1) autophagy.
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Sirtuins are also known as silent information regulator 2 (Sir2) proteins that are
nicotinamide adenine dineucleotide (NAD+)-dependent protein deacetylases (Donmez
and Outeiro, 2013). Sirt1 binds and deacetylates transcriptions factors, such as tau,
retinoic acid receptor beta, and NF-κB in the brain and also can lead to mitochondrial
biogenesis and fatty acid oxidation (Donmez and Outeiro, 2013). Wu and colleagues
(2012) showed that resveratrol preconditioning increased the catalytic antioxidant system,
methionine sulfoxide reductases A (MsrA), and protected against chloramine-T and 1methyl-4-phenyl-pyridium induced cell death (MPTP). Resveratrol treatment has also
been shown to protect against DA-induced oxidative stress in SH-SY5Y cells by the
reduction in the cleavage of PARP, an increase in Bcl-2, and activation of caspase-3 (Lee
et al., 2007).
1.10.2 Pinostilbene in vitro
Pinostilbene has been shown to have anticancer properties in a cell culture model
of prostate cancer by arresting cells in the G1/S phase and prohibiting cell growth (Wang
et al., 2010). Additionally, Chao and colleagues (2010) correlated that pinostilbene –
mediated decreases of of JNK-1, JNK-2, and c-jun-1 activation in SH-SY5Y cells
protected these cells from 6-OHDA-mediated neurotoxicity. The limited studies
involving pinostilbene increases to the novelty of the current study.
1.10.3 Wild blueberries in vitro
Wild blueberries have been shown to inhibit cancer cell proliferation (Adams et
al., 2011; Kausar et al., 2012; Rahal et al., 2013), decrease inflammation (McAnulty et
al., 2011; Gustafson et al., 2012), and protect cells from oxidative stress (Senevirathne et
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al., 2010; Papandreou et al., 2012). Wild blueberries have a significant amount of
antioxidant potential, as measured by oxygen radical absorbance capacity (ORAC;
Bagchi et al., 2006; Atala et al., 2009). The ORAC method of testing antioxidant capacity
of natural products is the most popular method and assess antioxidant capacity by
measuring the ability of a compound (antioxidant) to inhibit the consumption of a target
molecule (Lopez-Alarcon and Denicola, 2013). The antioxidant potential of wild
blueberries has been shown to protect against DNA damage via a decrease in gene and
protein expression of p53, phospho-p53 and p21 in hepatocarcinoma, HepG2 cells (Liu et
al., 2013). Blueberries have also been shown to improve vascular health through the
activation of the phophatidylinositol-3-kinase (PI3K) pathway, which resulted in cell
migration and angiogenesis (Tulio et al., 2012). Wild blueberry treatment in vitro has
been shown to attenuate neuronal sensitivity to Ca2+ fluctuations, which can occur with
age and cause a loss of function of cells ( (Joseph et al., 2008; 2010).
1.11. In vivo studies with natural products
1.11.1 Resveratrol and animal studies
Resveratrol has been shown to have protective effects in animal models of
cardiovascular disease (Lee and Moon, 2005; Das et al., 2006), diabetes (Zhang et al.,
2012; Guschlbauer et al., 2013), viral infections, and lung disease. For example, Lu and
colleagues (2008) found that resveratrol treatment attenuated acute pneumonia symptoms
and lung bacterial load through a reduction in lung inflammation and the activation of
cytokines, as well as an increase in natural killer (NK) cell activity. Topical application of
resveratrol inhibits herpes simplex virus from spreading in mice through inhibition of
20

NF-κB in the nucleus (Docherty et al., 2005; Faith et al., 2006). Faith and colleagues
(2006) showed that resveratrol inhibits NF-κB in the nucleus by providing data that the
unactivated form of NF-κB in the cytoplasm is unaffected by resveratrol treatment.
Relevant to the current study, resveratrol has been shown to be neuroprotective in
models of AD (Kumar et al., 2007), PD (Blanchet et al., 2008; Jin et al., 2008),
Huntington’s disease (HD; Kumar et al., 2006), ischemia (Wang et al., 2002; Das et al.,
2006; Della-Morte et al., 2009), traumatic brain injury (Ates et al., 2007) and epilepsy
(Wu et al., 2009). Neuroprotection mediated by resveratrol in the above mentioned
disease states is due to multiple factors, such as antioxidant and anti-inflammatory
effects.
1.11.2 Wild blueberries and animal studies
Dietary supplementation with wild blueberries has been shown to improve
cognition and motor coordination in a rodent model of Alzheimer’s disease as measured
by the Y-maze and Morris water maze (Joseph et al., 2003). Moreover, rats that were fed
a blueberry supplemented diet showed improvement in motor function as measured by
the rod walking, accelerod, and Morris water maze tests (Joseph et al., 1999). Joseph and
colleagues (2003) also showed that a blueberry supplemented diet improved cognitive
deficits in a rodent model of AD, as well as increased hippocampal levels of extracellular
signal regulated kinase (ERK) 1/2. Other studies have shown that antioxidant properties
of blueberries protect against oxidative stress and improve memory (Casadesus et al.,
2004; Andres-Lacueva et al., 2005; Duffy et al., 2008; Acosta et al., 2010).
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1.12 Clinical studies with natural products
1.12.1 Resveratrol and clinical studies
Resveratrol has been shown to have many beneficial effects, both in vitro and in
vivo, as described above. Red wine is considered the best source of resveratrol with
concentrations ranging from 4-40µM (Goldberg et al., 1996). However, clinical studies
with resveratrol have focused on the use of Concord grape juice or fruits to circumvent
deleterious effects of alcohol administration (Table 1; Constant, 1997). Pace-Asciak and
colleagues (1996) found that healthy male subjects that consumed grape juice had
reduced risk of atherosclerosis, as measured by reduced rates of plasma thromboxane B2,
and the IC50 (concentration required for 50% aggregation) for ADP and thrombininduced platelet aggregation after four weeks of daily consumption. Additionally, one
study showed the Concord grape juice improved verbal learning and enhanced verbal and
spatial recall in older adults with mild cognitive impairment (Krikorian et al., 2010).
Resveratrol supplementation (250mg/day) improved glycemic control in patients with
type 2 diabetes mellitus via improving hemoglobin A(1c) and systolic blood pressure
(Bhatt et al., 2012). Current clinical trials have not investigated resveratrol
supplementation with respect to motor coordination. However there have been clinical
trials that have analyzed the anti-inflammatory and antioxidant capabilities of resveratrol.
These studies have shown a decrease in ROS generation, as well as a decrease of IL-6,
NF-κB, and TNF-α (Culpitt et al., 2003; Ghanim et al., 2010; Karlsen et al., 2010). These
changes in ROS generation and suppression of cytokine activation may suggest that
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resveratrol could exhibit neuroprotective abilities in humans and thereby reduce motor
function decline.
1.12.2 Wild blueberries and clinical studies
Dietary supplementation with wild blueberries has been shown to have many
positive effects in one clinical trial that assessed mild cognitive decline associated with
verbal memory and visual-spatial memory (Krikorian et al., 2010; Malin et al., 2011;
Devore et al., 2012), motor coordination with age (Joseph, et al., 1999; Schrager et al.,
2012) and vascular health (Kalt et al., 2008; Kristo et al., 2011; Xie et al., 2011). For
example, two studies have shown that wild blueberry supplementation, juice or fruit,
improved memory in older adults (Krikorian et al., 2010; Joseph et al., 2010). Related to
the current study, elderly persons who ingested 2 cups of wild blueberry juice per day
showed improvements on multiple motor tasks, such as an increase in self-selected
walking speed, an increase in forced walking speed, a decrease in step errors during a
challenging walking task, and improvements in reaction times (Schrager et al., 2012). In
contrast, dietary supplementation of carrot juice had little to no effect on these
parameters. These data suggests that anthocyanins in wild blueberries may be responsible
for the positive effects in these motor tasks because carrots do not contain anthocyanins
(Schrager et al., 2012).
Several clinical studies that explored possible mechanisms for the effect of wild
blueberries on these behavioral and cognitive tasks have been conducted. Six weeks
following daily ingestion of a wild blueberry drink for six weeks (25g powder/drink)
levels of oxidized DNA bases and levels of H2O2-induced DNA damage were
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significantly reduced (Riso et al., 2013). Surprisingly, another study found that one
portion (300g) of blueberries has been shown to increase protection against H2O2-induced
DNA damage in healthy male subjects (Del Bo et al., 2013).
1.13 MAPK signaling
Mitogen-activated protein kinases (MAPKs) are enzymes that mediate a multitude
of processes, such as cell survival, differentiation, proliferation and apoptosis (Turjanski
et al., 2007). Three members of the MAPK family are extracellular signal-regulated
protein kinases 1/2 and 5 (ERK1/2 and ERK5). A protein cascade of phosphorylation by
upstream kinases activates ERK1/2 and ERK5. The upstream kinases for ERK1/2 and
ERK5 are MEK1/2 and MEK5, respectively.
1.13.1 ERK1/2
ERK1 and ERK2 are 42 and 44kDa proteins, respectively. They have
phosphorylation sites on the Thr–Glu–Tyr (TEY) in the protein kinase domain
(Roskowski Jr., 2012). ERK1/2 has been shown to be important for cell survival,
differentiation, cell adhesion, and migration (Nishimoto and Nishida, 2006; Krishna and
Narang, 2008). However, levels of phosphorylated (activated) ERK1/2 have been shown
to decline with age (Simonyi et al., 2003; Tortorella et al., 2004). As stated above,
oxidative stress is known to increase with age and the ERK1/2 signaling pathway is
activated in response to cellular stress (Roskowski Jr., 2012). H2O2-induced ERK1/2
activation is thought to play a critical role in cell survival in response to oxidative stress
in rat PC12 cells and primary cortical neurons (Guyton et al., 1996; Crossthwaite et al.,
2002). ERK1/2 activation was also shown to protect against hypoxia-induced cell death
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(Jin et al., 2002) and H2O2-mediated cell death (Crossthwaite et al., 2002). However,
some studies indicated the ERK1/2 activation plays a role in apoptosis associated with
oxidative stress (Ruffels et al., 2004; Kwon et al., 2011). The role of ERK1/2 is
dependent on cell-type, toxin, or tissue. Conflicting data exists, even within SH-SY5Y
cells. Some studies show that activation of ERK1/2 increases apoptosis (Arun et al.,
2013) and others show neuroprotection (Jantas and Lason, 2009; Decressac et al., 2012;
Minarini et al., 2012). Therefore, an aim of this study was to investigate the role of
ERK1/2 in a model of DA cell death and protection by natural compounds.
1.13.2 ERK5
ERK5, also known as big mitogen-activated protein kinase-1 (BMK-1), is the
most recently identified member of the MAPK family. ERK5 has a similar TEY
activation motif; however, what distinguish ERK5 from ERK1/2 are a large C-terminal
and a unique loop-12 sequence (Cavanaugh et al., 2000). The size of ERK5 is more than
double that of ERK1/2 at approximately 102kDa (Nithianandarajah-Jones, et al., 2012).
ERK5 has been shown to be highly active throughout prenatal neuronal development
with a sharp decrease in activity after birth (Liu et al., 2003). It has been suggested that
ERK5 plays a critical role in cortical development. ERK5 is also activated by stress, so it
is an important pathway to examine in oxidative stress (Nishimoto and Nishida, 2006).
Recent data from Dr. Jane Cavanaugh’s laboratory suggests the ERK5 activation declines
with age, predominately in DA regions of the brain. Due to an increase in oxidative stress
with age and a decrease in ERK5, this may indicate that ERK5 is important for DA cell
survival with age. As mentioned above, ERK5 may have distinct roles from ERK1/2, but
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due to a lack of specific inhibitors, their roles were not well understood. Recently,
XMD8-92 has been shown to inhibit ERK5 phosphorylation in cancer cells (Yang and
Lee, 2011; Yang et al., 2010). BIX02189 has also recently been synthesized and shows
ERK5 specific inhibition in PC12 cells (Obara et al., 2009), cardiac myocytes (Kimura et
al., 2010), and C6 glioma cells (Obara et al., 2011).
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Figure 3. MAP Kinase Signaling cascade.
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1.13.3 Inhibitors of ERK1/2 and ERK5
While the ERKs have been widely studied, the distinct roles of ERK1/2 versus
ERK5 are not yet well defined. MAPKs are highly conserved enzymes and available
pharmacological inhibitors of ERK1/2, such as U0126 and PD98059, were not specific
for the ERK1/2 pathway in all cell types (Nishimoto and Nishida, 2006). For example,
Yu and colleagues (2012) found that in a rodent model of cystitis, U0126 and PD98059
inhibited both MEK1/2 and MEK5. Another study showed that PD98059 and U0126
specifically inhibited ERK1/2 while ERK5 activity unaffected in multiple cell lines
(kidney cells: RCC4, breast cancer cells: MCF-7; and human osteosarcoma cells: U2OSHRE-luc; Sutton et al., 2007). More recently, MEK5 specific inhibitors, BIX02189
(Obara and Nakahata, 2010; Yang and Lee, 2011) and XMD8-92 (Yang and Lee, 2011),
have been synthesized, that have been shown to be more specific for ERK5 in several cell
culture models.
1.13.4 Resveratrol and ERK signaling
In natural killer, NK2 cells, resveratrol was shown to increase phosphorylation of
ERK1/2 possibly through the natural killer receptor, NKG2D, and treatment with
ERK1/2 specific inhibitors blocked NK cell cytotoxicity (Lu and Chen, 2010). In SHSY5Y cells, resveratrol activated (1pM-10µM) and inhibited (50-100µM) ERK1/2 in a
concentration-dependent manner (Miloso et al., 1999).
1.13.5 Pinostilbene and ERK signaling
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As mentioned above, there is little research on pinostilbene, in vivo and in vitro.
However, Chao and colleagues (2010) showed that pinostilbene has been shown to
decrease activation of JNK-1, JNK-2, and c-jun-1 in SH-SY5Y cells. This data indicates
that pinostilbene is able to modulate the JNK MAPK signaling pathways and, therefore,
may possibly affect other MAPK pathways, including the ERK signaling cascades.
1.13.6 Wild blueberries and ERK signaling
A few groups have shown that wild blueberry supplementation improves memory
in rodents via the activation of ERK1/2 in the hippocampus (Williams et al., 2008;
Rendeiro et al., 2012). However, Vuong and colleagues (2010) have shown that blueberry
juice protects neurons from H2O2-induced oxidative stress through inhibition of ERK1/2
mediated cell death. Therefore, although a hypothesis of this study is that wild blueberry
supplementation will increase ERK1/2 activation and thereby protect DA cells from
oxidative stress-induced cell death. However, it is possible that wild blueberry treatment
will decrease or have no effect on ERK1/2 activity.
In conclusion, the first two aims of this research are to evaluate a widely used
pharmaceutical product,

L-DOPA,

and natural products, including resveratrol,

pinostilbene, and wild blueberries, as effective treatments for age-related motor deficits
using behavioral tests of motor coordination and spontaneous activity and to investigate if
there is a difference in the effectiveness of the isolated natural compound, resveratrol,
and whole foods, such as wild blueberries. Finally, using the SH-SY5Y dopaminergic
cell line, the third aim is to examine the effect of these natural products on DA neuronal
survival and ERK signaling. Together these aims contribute to the overall goals of this
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study, which are to begin to identify possible treatments for age-related motor deficits
and to elucidate some of the mechanisms by which these compounds may produce
beneficial effects.
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Chapter 1
The Effect of L-DOPA on age-related motor deficits in mice
2. RATIONALE AND HYPOTHESIS
2.1 RATIONALE
Aging is usually accompanied by a decline in motor function, a phenomenon that
can be observed in laboratory animals as well as in humans. For example, rodents
typically exhibit a decline in spontaneous motor activity and motor coordination with age
(Cantuti-Castelvetri et al., 2003; Fleming et al., 2004; Boger et al., 2006; Colebrooke et
al., 2006). Such motor deficits have been shown to arise following alterations in the
dopamine (DA) neuronal system (Packard and Knowlton, 2002). Indeed, as seen in
studies of Parkinson's disease (PD), many of the motor deficits are strongly correlated
with the loss of the DA neurons of the nigrostriatal projections (Eriksen, et al., 2009). LDOPA, which increases the availability of DA in striatum, is able to temporarily improve
motor function in PD patients (Obesa et al., 2008; Olanow et al., 2009).
The efficacy of L-DOPA in PD suggests the possibility that the drug may also be
effective in the treatment of motor dysfunction that occurs with normal aging; a clinical
problem for which there is no standard treatment. To test this hypothesis, the effects of LDOPA on balance, motor coordination, and spontaneous activity were examined in young
and old male mice using challenge beam and cylinder tests, respectively (Fleming et al.,
2006; 2004a; 2004b). Following behavioral testing, DA and DA metabolite content were
determined in the striata of these animals. Finally, in a separate group of animals, the
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expression of tyrosine hydroxylase (TH) and the high affinity DA transporter (DAT)
were determined in the striata one week following behavioral testing.
2.2 HYPOTHESIS
L-DOPA

administration will attenuate age-related motor deficits in C57Bl/6 mice.

3. MATERIALS AND METHODS
3.1 Animals
C57Bl/6 mice were chosen as an aging mouse model. These mice display less comorbidities than other mouse models. Young (2.5 mo) and old (20.5 mo) male C57BL/6
mice (Harlan Laboratories, Indianapolis, IN) were housed 3 per cage and maintained on a
12 h light:dark cycle with ad libitum access to food and water. The animals were utilized
in compliance with all applicable laws and regulations as well as principles expressed in
the National Institutes of Health, University of Pittsburgh, and the Guide for the Care and
Use of Laboratory Animals.
3.2 Treatment Groups
Mice were given benserazide (12.5 mg/kg; i.p., cat # B7283, Sigma, St Louis,
MO) to block peripheral decarboxylation of L-DOPA, followed 10 min later by L-DOPA
(15 mg/kg, i.p., cat # D1507, Sigma) or an equivalent volume of saline vehicle.
3.3 Behavioral Analysis
3.3.1 Challenge beam task
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Animals were tested on the challenge beam to assess motor performance as
previously described (Fleming et al., 2004; Fleming and Chesselet, 2005; Hwang et al.,
2005). Briefly, mice were trained to traverse an elevated beam (4 segments, 25 cm long
by 3.5 cm at the widest segment, narrowing to 0.5 cm in 1 cm increments) and enter their
home cage on 2 separate days 24 hours apart. One week after training, wire mesh with 1
cm2 openings was placed over the beam segments and the animals were videotaped and
timed during their traversals. Videotapes were viewed and rated in slow motion for the
number of steps, time to cross, and errors by an investigator blinded to the treatment
group.
3.3.2 Spontaneous activity
For these experiments, a small, transparent, Plexiglas cylinder (height 15.5 cm,
diameter 12.7 cm) was placed on a piece of glass that was elevated by four pedestals (6
in). A mirror was placed underneath the glass and angled towards the video camera so
that the mice could be viewed from below. Animals were videotaped in the cylinder for 3
min and videos were analyzed for forelimb steps, hind-limb steps, rears, and time spent
grooming by an investigator blinded to the treatments. A step was counted when the
animal moved both paws across the glass and a rearing was considered as a vertical
movement with both front paws leaving the glass floor. Values were calculated as the
mean ± SEM.
3.4 Tissue processing
Mice were decapitated one week following the last behavioral test. Striata were
rapidly dissected, frozen on dry ice, and stored at -80°C until assayed. Striatal samples
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were sonicated in 0.1N perchloric acid (20μl/mg wet tissue weight) for analysis of DA
levels or in ice cold lysis buffer (20mM Tris, pH 6.8, 137mM NaCl, 25mM βglycerophosphate, pH 7.14, 2mM NaPPi, 2mM EDTA, 1mM Na3VO4, 1% Triton X-100,
10% glycerol, 5μg/ml leupeptin, 5μg/ml aprotinin, 2mM benzamidine, 0.5mM DTT and
1mM PMSF) for analysis of two phenotypic markers of DA neurons, TH and DAT.
3.5 Western Blot analysis for DAT and TH
Protein content was assessed by bicinchoninic acid assay (Pierce, Rockford, IL)
and 20μg of protein was loaded on an SDS PAGE gel and transferred to an ImmobilonFL PVDF membrane (Millipore, Billerica, MA). Membranes were washed in Trisbuffered saline with 0.1% Tween (TTBS) and blocked for 1 hr in a fish-serum based
blocking solution (LI-COR Biosciences, Lincoln, NB) at room temperature. Membranes
were then incubated overnight at 4°C in monoclonal rat anti-DAT (1:2000; Chemicon, #
MAB369, Temecula, CA), monoclonal mouse anti-TH (1:20,000, Chemicon, #
MAB318), or monoclonal mouse anti-α-tubulin (1:50,000, Sigma Clone B512 T5168).
Binding was visualized with infrared secondary antibodies fluorescing at 700 nm (goat
anti-rat for DAT; goat anti-mouse for tubulin) or 800 nm (goat anti-mouse for TH;
Odyssey Imaging; LI-COR) for 1 hr at room temperature (1:10,000) in blocking solution.
Blots were scanned on an Odyssey Imager and quantified with Odyssey software, using
background subtraction above and below each band. Grayscale images were used for
quantification and the images were pseudo-colored red (700 nm) and green (800 nm) to
delineate DAT and TH using distinct fluorescent wavelengths.
3.6 HPLC analysis for dopamine and metabolites, DOPAC and HVA
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Striata were sonicated in 0.1N perchloric acid (20µL/mg of tissue). After filter
centrifugation, an aliquot was analyzed by HPLC for DA, 3,4- dihydroxyphenylacetic
acid (DOPAC), and homovanillic acid (HVA) content as previously described (Smith et
al., 2002). An aliquot of each sample was injected onto an ESA C18 column (2.1 × 150
mm, ESA, Inc., Chelmsford, MA). The mobile phase consisted of 75mM H2NaPO4,
1.7mM octanesulfonic acid, 25mM Na2EDTA 0.00001% triethylamine (v/v), and 10%
acetonitrile (v/v), pH 3.0 and was pumped through the system at a rate of 0.3 ml/min
using an ESA LC-10AD pump (ESA Inc., Chelmsford, MA). Samples were detected
coulometrically using an ESA Coulochem Model 4100A detector, an ESA Model 5010
conditioning cell, and an ESA Model 5014B microdialysis cell (ESA Inc., Chelmsford,
MA). The settings for detection were E1 = −0.26 V, E2 = +0.28 V, guard cell = +0.4 V.
The limits of detection were in the femtomole range. Quantification was based on
standard curves for DA, DOPAC, and HVA.
3.7 Statistical analysis
All statistical tests were performed using Graph Pad Prism. The data in figures 1
and 2 were analyzed using a two-way ANOVA (p<0.05) followed by post hoc
comparison using a Bonferroni multiple comparison test. The data in figures 3, 4, and 5
were analyzed using an unpaired t-test with a 95% confidence interval.
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4. RESULTS
4.1 L-DOPA reverses the age-related decline in motor coordination
The challenge beam task was used to measure motor coordination in this aging
mouse model. Aged (20.5 mo) C57Bl/6 male mice made significantly more errors on the
challenge beam task than young (2.5 mo) mice (Fig. 4). Treatment with L-DOPA
decreased the number of errors made by the old mice to that of young, saline treated
animals (Fig. 4). L-DOPA had no effect on the motor coordination of young animals.
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4

Figure 4. L-DOPA decreases the number of errors made by old animals on the
challenge beam task.
Results are presented as mean ± SEM, n = 6-9 per group. Old animals
made significantly more errors as compared to their young counterparts (*p<0.05 in
comparison to young saline). L-DOPA treatment (15mg/kg) reversed age-related motor
deficits in old animals (**p<0.05 in comparison to old saline). Data were analyzed using
a two-way ANOVA followed by post hoc comparison using a Bonferroni multiple
comparison test.
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4.2 L-DOPA does not alter spontaneous activity
In order to determine if age has an effect on spontaneous activity, the cylinder test
was used to measure four parameters for exploration used to determine spontaneous
activity were rearing, forelimb and hind-limb steps and grooming. Each mouse was
placed in a Plexiglas cylinder and videotaped the mouse for three minutes. Aged mice did
not display deficits in any of these parameters as compared to young mice (Fig. 5).
Moreover, L-DOPA treatment did not affect any of these behaviors in young or old mice.
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5

Figure 5. Number of rears did not significantly change with age or L-DOPA
treatment.
Results are presented as mean ± SEM, n = 6-9 per group. Young and old animals made
similar numbers of rears in the cylinder test. L-DOPA had no effect on rears in young
or old animals. Data were analyzed using a two-way ANOVA followed by post hoc
comparison using a Bonferroni multiple comparison test.
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4.3 DA, DOPAC, and HVA levels are not changed with age
To determine if age altered the DA neuronal system, DA, DOPAC, and HVA
levels were measured by HPLC in the striatum of young (2.5 mo) and old (20.5) mice.
The levels of DA, DOPAC, and HVA were not altered in an age-related manner in this
mouse model (Fig. 6A). Administration of L-DOPA did not change the amount of DA or
metabolites in young or old mice (Fig. 6B).
Western blot analysis was performed to determine if the protein expression of the
dopamine transporter (DAT) or tyrosine hydroxylase (TH) was altered with age in the
striatum. Neither DAT nor TH expression were altered with age (Fig. 7A and 7B).
Administration of L-DOPA did not change the expression of TH or DAT in the striatum
of young or old mice (Fig. 7).
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6A

6B

Figure 6: DA, DOPAC, and HVA levels are unchanged with age.
Results are presented as mean ± SEM. (A) Striatal dopamine levels and metabolites
are unchanged with age. Accordingly, dopamine turnover was also unchanged with
age. (B) L-DOPA administration did not alter striatal DA levels or metabolites. Data
were analyzed using a two-way ANOVA followed by post hoc comparison using a
Bonferroni multiple comparison test.
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7

7

Figure 7: Phenotypic markers of DA neurons are unchanged with age or L-DOPA
adminstration.
Results are presented as mean ± SEM. (A) The dopamine transporter, DAT, was
unchanged with age. Administration of L-DOPA did not alter striatal DAT (B)
Tyrosine hydroxylase (TH), the rate limiting enzyme in DA synthesis, was unchanged
with age or with L-DOPA administration. Data were analyzed using an unpaired t-test
with a 95% confidence interval.

42

5. DISCUSSION
A loss of motor coordination, which can lead to an increase in slips and falls
(Schoene et al., 2013), has been noted with age (Potvin et al., 1980). With the current and
projected increase in the percentage of the population 65 years and older, this loss of
motor coordination creates a national health care crisis. Currently, there are no mainstay
therapies for motor deficits that are associated with non-diseased, normal aging.
However, in one clinical trial, L-DOPA, a first-line therapy in the treatment of motor
symptoms associated with PD, was shown to improve fine motor control in elderly
patients (Floel et al., 2008). The current study examined the effect of L-DOPA on agerelated motor deficits in a mouse model of aging.
The challenge beam task was used to measure the effect of aging on motor
coordination. The use of the challenge beam is a novel behavioral test that measures the
number of slips or errors, steps, and amount of time it takes to cross the beam (Fleming et
al., 2005; Fleming et al., 2006; Hwang et al., 2005). Aged animals made significantly
more errors on the beam than young animals (Fig. 4). Administration of L-DOPA
decreased the number of errors to that of the young saline group (Fig. 4). However, LDOPA treatment did not affect the number of errors made by young animals. These data
suggest that L-DOPA treatment reverses age-related motor deficits in coordination as
measured by the challenge beam task. This study is the first to use the challenging beam
task to analyze age-related motor deficits. Other studies have shown a decrease in motor
performance with age using a multitude of other behavioral tests such as, accelerating
rotarod test (Colebrooke et al., 2006; Esteban et al., 2010; Parameshwaran et al., 2010),
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wire hanging (Thiruchelvam et al., 2003; Takahashi et al., 2009), balance beam (Emerich
et al., 2008), and hind-limb extension (Takahashi et al., 2009). However, the challenge
beam task is a more sensitive test and can detect changes in fine motor coordination
before traditional behavioral tests and, importantly, before a significant loss of DA
neurons in the substantia nigra (SN; Fleming et al., 2004).
Some years ago, a report appeared in which the effects of L-DOPA were
examined in 10 healthy elderly volunteers (Newman et al., 1985). In this study, L-DOPA
had no effect on movement velocity, reaction time or tremor (Newman et al., 1985).
However, the number of people in this study was very limited and the investigators did
not measure motor coordination per se. In agreement with the results of the current study,
a more recent study showed that L-DOPA improves upper limb function in otherwise
normal aged rhesus monkeys (Grondin et al., 2000). Furthermore, in a study of motor
memory performance in the elderly, L-DOPA enhanced the effects of training on motor
memory formation, in part via an increase in DA release in the caudate nucleus (Floel et
al., 2008). Therefore, one possible explanation for the effect of L-DOPA on motor
coordination in the C57Bl/6 aged mouse model is that it reverses age-related losses of
striatal DA or turnover.
In the present study, the decline in motor function was not accompanied by agerelated alterations in DA, DOPAC, or HVA striatal content or DA turnover as determined
by the ratio of DA metabolite levels to DA levels (Fig. 6A). This is in contrast to research
that has shown that there are age-related decreases in striatal DA (Emborg, 1998;
Colebrooke et al., 2006; Cruz-Muros et al., 2007), and decreases (Esquifino et al., 2002;
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Purdom et al., 2003) or increases (Yurek et al., 1998) in DA turnover. However, in
agreement with the results in these aged C57Bl/6 mice, others have reported no change in
striatal DA content with age (Bowenkam et al., 2000). Together, these data suggest that
there may be species differences in alterations of the DA system that occur with age.
Treatment with L-DOPA did not affect the amount of striatal DA, DOPAC or
HVA (Fig. 6B). While these results may seem surprising, the animals were sacrificed one
week after L-DOPA treatment. The half-life of L-DOPA is 60-90 min (Poewe and
Mahlkne, 1997). Therefore, the effect of L-DOPA on DA and DA metabolites may be
transient and unable to be observed one week following treatment.
In addition to age-related losses of striatal DA, striatal TH and DAT (Troiano et
al., 2010; Yue et al., 2012) content have been reported to decline with age (Meng et al.,
1999; Salvatore et al., 2003). However, in the present study there was not an age-related
decrease in either striatal TH or DAT expression (Fig. 7). Similar to these results,
Salvatore and colleagues (2009) did not observe alteration in total striatal DAT or DA
content with age; however, they noted an age-related decrease in DAT protein recovered
from the plasma membrane. Together with the data from the current study, these results
suggest that internalization of DAT, but not decrease in total DAT, may occur with age. It
is also possible that in these mice, male C57Bl/6, there is no change in DAT with age.
Other alterations in the DA neuronal system that have been observing in aging
models include decreases in D1 (Wang et al., 1998) and D2 (Hara et al., 1992; Roth and
Joseph, 1994; Volkow et al., 1998) and DA receptor expression. Therefore, it is possible
that a decrease in DA receptors, and thereby a decrease in DA signaling, occurred in our
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animal model and contributed to the age-related decline in motor function. L-DOPA, in
turn, may have increased DA neurotransmission and/or signaling to alleviate the loss of
motor coordination noted with age (Boger et al., 2010; Hoekzema et al., 2010; Yue et al.,
2012).
Striatal dopamine release has also been shown to decline with age (Yurek et al.,
1998; Gerhardt and Maloney, 1999; Stanford et al., 2000). Again, it is possible that DA
release was decreased with age in our model to produce motor deficits and L-DOPA
treatment increased DA release to restore motor function.
Finally, DA cell bodies that reside in the SN have been shown to degenerate with
age (McNeill et al., 1984a; 1984b; Boger et al., 2006). Therefore, age-related
degeneration of these DA neurons may have occurred in our model even though we did
not observe a loss of DA content in the striatum. Future studies will explore these
possibilities.
In addition to possible effects of L-DOPA on DA neuronal parameters that were
not measured in this study (i.e. DA receptor levels, DAT internalization, DA release), a
possible explanation for the effect of L-DOPA on motor coordination in these aged
animals is that it increases striatal noradrenergic function. Rommelfanger and colleagues
(2007) found that dopamine β-hydroxylase knockout mice (Dbh−/−), which lack
norepinephrine (NE) but have normal DA levels in the striatum, have a significant loss of
motor coordination as compared to heterozygous litter mates (Dbh+/−) as measured by
the same challenge beam test used in this study. Therefore, it is possible that in our
animals there was an age-related decline in NE levels that contributed to the motor
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dysfunction and L-DOPA increased NE levels and signaling in the aged animals to restore
coordination.
One other possibility is that there was a loss of equilibrium between DA and
acetylcholine (Ach) in the striatum of our aged animals (Di Chiara et al., 1994; Calabresi
et al., 2000) and L-DOPA treatment restored the balance between these neurotransmitters.
Some of the motor symptoms associated with PD can be reversed by inhibiting Ach
activity, which suggests that DA-Ach interactions are important for motor coordination
(Berg et al., 1987). It is possible that there was a decrease in Ach that changed the DAAch balance and contributed to the age-related motor deficits in these C57Bl/6 mice,
however, this parameter was not investigated.
In contrast to the loss of motor coordination noted with age on the challenge beam
test, spontaneous activity as measured by number of rears during the cylinder test was not
significantly decreased in C57Bl/6 aged male mice (Fig. 5). Interestingly, rearing or
vertical movement has been shown to be mediated by DA neurotransmission (Kalivas et
al., 1984; Koene et al., 1993; Swanson et al., 1997). The data in the current study support
a role for DA in rearing behavior in this aging mouse model as age-related deficits in
rearing behavior or striatal DA and DA metabolites were not observed. Moreover, the
fact that there was no loss in spontaneous activity in this aging model allows for
interpretations of the challenge beam test without the confounding factor of a loss of
spontaneous movement in old animals.
In contrast to the effect of L-DOPA on motor coordination, L-DOPA treatment did
not increase spontaneous activity in the young or old mice. The cylinder test was
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performed within 30 min following the L-DOPA injection and there was no change in the
average number of rears with age or L-DOPA treatment. As mentioned above, when
measured one week following L-DOPA treatment, striatal DA or DA metabolites levels
were unchanged as compared to the vehicle treated animals. As L-DOPA is known to
increase extracellular DA in the striatum (Obesa et al., 2008; Olanow et al., 2009), we
hypothesized that L-DOPA would increase spontaneous activity.
L-DOPA

therapy, which has been used for more than 40 years in the treatment of

PD (Mercuri and Bernardi, 2005) is well tolerated in early PD and the side effects that
typically appear in the later stages of PD are likely to be a consequence of the progressive
loss of DA neurons that accompanies the disease and thus may not be a factor in normal
aging. Therefore, on the basis of the data from the current study, the few related findings
that have appeared in the literature, and the apparent lack of side effects of the drug in
otherwise normal adults, we suggest that with further investigation L-DOPA could be
considered as a useful treatment for aged-related motor decline.
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Chapter 2
The effect of natural products on age-related motor deficits in mice
6. RATIONALE AND HYPOTHESIS
6.1 RATIONALE
L-DOPA

only treats the motor symptoms of PD and does not halt the progressive

degeneration of nigrostriatal tract. For these reasons, L-DOPA works optimally early in
the treatment of the PD (for the first 2 years); however, as the progression of PD
continues (5–10 years), the efficiency of L-DOPA decreases, such that many patients
develop motor fluctuations (‘wearing-off’ phenomenon) and involuntary movements or
dyskinesias (Marsden and Parkes, 1976; Shimizu and Ohno, 2012). Importantly, once
these dyskinesias have developed, they are irreversible, even with cessation of L-DOPA
treatment (Iderberg et al., 2012). Consequently, while L-DOPA was an effective treatment
for motor deficits in our aged mouse model, our study was short-term and did not address
the long-term effects of L-DOPA. Therefore, a literature was done to investigate other
possible treatments for age-related motor decline that may not have such detrimental side
effects. One such treatment is the natural compound, resveratrol.
Resveratrol is a compound found in many whole foods, including grapes and
blueberries. These whole foods and many others, including walnuts and spinach, are
natural sources of antioxidants. One hypothesis for the pathology that underlies motor
deficits that occur with age is that there is an increase in oxidative stress with age leading
to an increase in neuronal cell death (Stadtman, 1992; Harman, 1992; Ames et al., 1993).
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DA neurons are particularly sensitive to oxidative stress (Foley and Riederer, 2000).
Therefore, administration of exogenous antioxidants could provide an effective treatment
for this imbalance of ROS.
A caveat for using resveratrol is that is has limited bioavailability (Andlauer et al.,
2000; Soleas et al., 2001) and high doses may actually be toxic to neurons (Johnson et al.,
2011). Therefore, pinostilbene, a resveratrol analog, that has also been shown to protect
neurons against oxidative stress in vitro and in vivo (Chao et al., 2010) became of interest
in the current study.
Finally, an intriguing theory in natural product research is that the isolated
compounds are more effective in their natural environment, such as a whole fruit. Wild
blueberries are one of these whole foods that contain resveratrol (Rimando et al., 2004)
and have been shown to have neuroprotective properties (Kumar et al., 2006; Kumar et
al., 2007; Blanchet et al., 2008; Jin et al., 2008). Therefore, the current study was to
examine the effect of these natural products, either as isolated compounds or as the whole
food, on age-related motor deficits in the aged C57Bl/6 mouse model.
6.2 HYPOTHESIS
Dietary supplementation with resveratrol, pinostilbene, or wild blueberries will
attenuate age-related motor deficits. Wild blueberries will be more effective than
resveratrol and pinostilbene at attenuated the loss of motor function noted with age.
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7. MATERIALS AND METHODS
7.1 Animals
Young (2 mo), middle-aged (10 mo), and old (22 mo), male, C57BL/6 mice were
obtained from the NIA aging colony (Charles River, New York, NY) and were housed
singly. All animals were maintained on a 12 hr light/dark cycle. Water and food were
supplied ad libitum until the study began. All procedures were conducted in accordance
with the guidelines for the NIH Care and Use of Laboratory Animals and approved by the
Duquesne University Institutional Animal Care and Use Committee.
7.2 Resveratrol or pinostilbene dietary supplementation
In order to determine the average amount of food consumption for mice, we
discussed rodent behavior and feeding habits with the Duquesne University animal
facilities manager, Denise Butler-Buccilli. Mice were given 6g per day of resveratrol- or
pinostilbene-supplemented diet (120 mg/kg of diet) for 8 weeks. The diets were prepared
at Harlan Teklad (Madison, WI) by adding crystalline resveratrol (TCI America,
Waltham, MA) or pinostilbene (synthesized by Dr. Cassia Mizuno, ARS USDA facility,
University, MS) to the control diet, which is a modification of the standard rodent chow
supplied at the Duquesne University Animal Facility (Purina Rodent Chow; 6 gm/day,
0.004% w/w). Food consumption was measured daily and mice ate ~4.5 grams/daily.
Therefore, calculating the amount of resveratrol and pinostilbene consumed, we
determined that the mice ate 0.54 mg/kg of body weight daily. The average weight of the
mice during the study was 30 g, therefore, calculating for the average human male (70
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kg), the dose that a human would have to eat to be equivalent to this study would be 1.26
g.
7.3 Wild Blueberry Dietary Supplementation
Mice were fed a wild blueberry powder supplemented diet (2%; Harlan Teklad)
for 8 weeks. The wild blueberry powder was a generous gift from the Wild Blueberry
Association (Nutraceuticals, Momence, IL). The diet was prepared at Harlan Teklad by
adding wild blueberry powder to the control diet, which is the standard rodent chow used
in the Duquesne University animal facility. The amount of corn in an additional control
diet was adjusted to account for the added quantity of wild blueberries and make an isocaloric control. Mice on the wild blueberry diet ate approximately 4.5grams of diet/daily.
We calculated the amount of wild blueberries consumed daily, each mouse ate
approximately 90mg. The average weight of the mice over the course of the study was
30g. Therefore, calculating for the average human male (70kg), the equivalent dose
would be 210g, which would be approximately 1.5 to 2 cups of wild blueberries daily.
7.4 Behavioral analysis (see Chapter 1 Methods pg 30-31)
7.4.1 Challenge beam test
7.4.2 Spontaneous Activity
7.5 Tissue processing
Mice were decapitated 24 hrs after the cylinder test for spontaneous activity, and
the striatum was rapidly dissected, frozen on dry ice, and stored at -80°C until assay. The
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hindbrain was stored in fix solution (4% formaldehyde/4% NaF in PB) for one week and
then changed to a 30% sucrose solution in 1XPBS. Samples were sonicated in 0.1N
perchloric acid (20μl/mg wet tissue weight) for analysis of DA levels or in ice-cold lysis
buffer for analysis of two key phenotypic markers of DA neurons, TH and DAT. The
lysis buffer consisted of 20mM Tris, pH 6.8, 137mM NaCl, 25mM β-glycerophosphate,
pH 7.14, 2mM NaPPi, 2mM EDTA, 1mM Na3VO4, 1% Triton X-100, 10% glycerol,
5μg/ml leupeptin, 5μg/ml aprotinin, 2mM benzamidine, 0.5mM DTT and 1mM PMSF.
7.5 Western Blot Analysis
One half of the striatum from each animal was sonicated in ice-cold lysis buffer.
Protein (60µg) was run on an 8% SDS-PAGE minigel at 100V for 2 hrs. The gels were
then transferred to nitrocellulose membranes (Li-Cor Biosciences; Lincoln, NE) and were
blocked for 1h at room temperature with shaking. The membranes were incubated in
mouse anti-ERK1/2 (1:1000, catalog # 9107; Cell Signaling Technology, Danvers, MA),
rabbit anti- phospho-ERK1/2 (1:1000, catalog # 9101; Cell Signaling Technology) rabbit
anti-ERK5 (1:1000, Sigma, catalog # 1523), rabbit anti-phospho-ERK5 (1:1000, catalog
# 3371; Cell Signaling Technology), rabbit monoclonal anti-DAT (1:3000, catalog #
AB2231, Millipore), mouse anti-TH (1:2000; catalog # MAB318, Millipore), or GAPDH
(1:1000, Millipore) antibodies overnight in casein blocking buffer (Li-Cor Biosciences).
The membranes were washed four times with 1XPBS/0.1%Tween-20/0.01%NaN3
followed by a one-hour incubation with IR680-labeled goat anti-rabbit or IR800-labeled
goat anti-mouse secondary antibody (1:10,000, Li-COR Biosciences). Blots were scanned
on an Odyssey Imager and quantified with Odyssey software, using background
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subtraction above and below each band. Grayscale images were used for quantification,
and the images were pseudo-colored red (700 nm, goat anti-rabbit) and green (800 nm
goat anti-mouse) to delineate using distinct fluorescent wavelengths.
7.6 HPLC Analysis (see Chapter 1 Methods, pg 32-33)
7.7 Gas chromatography-Mass spectrometry (GC-MS)
7.7.1 Compounds
Resveratrol was a commercial sample (ChemPacific, Baltimore, MD).
Pinostilbene was synthesized by Dr. Cassia Mizuno in Dr. Agnes Rimando’s laboratory
following published procedures (Polunin and Schmalz 2004). Briefly, pterostilbene was
methylated with methyl iodide to obtain trimethoxystilbene. Trimethoxy stilbene was
then demethylated with lithium thioethoxide in dimethylformamide (160ºC for 2h; 67%
yield). The compound identity and configuration was established by nuclear magnetic
resonance spectroscopy.
7.7.2 Analysis of stilbenes by gas chromatography-mass spectrometry (GC-MS)
Tissue samples were kept in -80°C freezer until used for analysis. Tissues were
thawed on ice, then homogenized in 150µl of sodium phosphate buffer (0.2M NaHPO4:
0.2M Na2HPO4; 80:20), pH 7.4, and centrifuged for 15 mins at 7000g, 4°C. The pellet
was homogenized a second time with 150µl of phosphate buffer. The supernatants were
combined; half-volume was treated with ß-glucuronidase (5000 U/ml potassium
phosphate buffer, 75mM, pH 6.8; 50 µl/125µl extract) and incubated at 37°C with
shaking at 750 rpm for 20 hrs. Potassium phosphate buffer was added to the other half54

volume as control. The mixture was partitioned with ethyl acetate (200µl x 3). The
combined ethyl acetate extracts was dried under a stream of nitrogen, and derivatized
with

30μL

of

a

1:1

mixture

N,O-bis[trimethylsilyl]trifluoroacetamide

and

dimethylformamide (Pierce Biotechnology, Inc., Rockford, IL, USA), heated at 70°C for
40 min, and used for analysis of pinostilbene and resveratrol.
Analysis of pinostilbene and resveratrol in the HPC tissues by GC-MS (JEOL
GCMate II Instrument; JEOL USA Inc., Peabody, MA, USA) was performed using a
J&W DB-5 capillary column (0.25 mm internal diameter, 0.25μm film thickness, and 30
m length; Agilent Technologies, Foster City, CA, USA). The GC temperature program
was: initial 190°C, increased to 242°C at 30°C/min rate, increased to 248°C at the rate of
0.4°C/min, then finally increased to 300°C at the rate of 30°C/min and held at this
temperature for 0.5 min. The carrier gas was ultrahigh purity helium (1 mL/min flow
rate). The injection port, GC-MS interface, and ionization chamber were kept at 250,
230, and 230°C, respectively. The volume of injection was 2μL (splitless injection). The
mass spectrum was acquired in the positive, selected ion-monitoring mode; electron
impact 70 eV. The retention time for pinostilbene was 10.4 min (monitored with m/z
388, 373, and 356). The retention time for resveratrol was 11.2 min (monitored with m/z
446, 431, and 373).

GC-MS analyses were done in duplicates.

Quantitation of

pinostilbene and resveratrol was done using external standards. These analyses were done
in the laboratory of our collaborator, Dr. Agnes Rimando.
7.8 Hindbrain analysis
7.8.1 Tissue processing
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Brains were stored at 4ºC in cryoprotectant (30% sucrose in 1XPBS) until
processing. Approximately, six separate series of 30μm coronal brain sections were
obtained from each hindbrain with a sliding microtome (Microm HM 450, Thermo
Scientific, Asheville, NC). After the sections were collected, the slices were analyzed for
TH+ using a protocol established and verified to be as accurate as stereology by Tapias
and colleagues (2012). The immunostaining and analysis of these hindbrain sections were
done in collaboration with Dr. Victor Tapias in Dr. Timothy Greenemyre’s laboratory in
the Pittsburgh Institute for Neurodegenerative Disease at the University of Pittsburgh,
Pittsburgh, PA. Selected sections (3–4 sections per well of a 24-well plate) were washed
3 times in 1XPBS, pH 7.6, for 10 min and incubated with 1% Triton X-100 in PBS
solution for 5 hr at 4 °C. Next, sections were washed 3 times for 10 min in 1XPBS and
blocked with 10% normal donkey serum and a permeabilizing reagent (0.3% Triton X100) in 1XPBS solution for 30 min at room temperature. Subsequently, sections were
incubated in 1XPBS/ 0.3% Triton X-100 (to facilitate antibody access to the epitope) for
72 hr at 4°C with the following primary antibodies directed against the protein of interest:
1) mouse monoclonal antibody for MAP2 (1:2000; #MAB378, Millipore), a cytoskeletal
protein that binds to tubulin and stabilizes microtubules and is essential for the
development and maintenance of neuronal morphology, was used for neuron staining and
2) sheep polyclonal antibody for TH (1:2000; #AB1542, Millipore), the rate-limiting
enzyme in DA synthesis, was used to visualize DA neurons. After an additional
incubation in primary antibody solution for 1 hr at RT, the sections were washed 3 times
for 10 min each in 1XPBS to remove unreacted primary antibodies and were then
incubated with secondary antibodies: Cy3-conjugated anti-sheep antibody (1:500; #713-
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165-003, Jackson-ImmunoResearch) and Alexa Fluor-conjugated 647 anti-mouse
antibody (1:500; #A31571, Invitrogen) for 2 hr at RT. Tissue sections were then washed
twice in 1XPBS for 10 min and H 33342 (1:3000; #B2261, Sigma-Aldrich) reagent was
used as a nuclear counterstain for 5 min at RT. Finally, after the sections were washed 3
times with 1XPBS for 10 min each, the sections were mounted onto plus-coated slides
and cover-slipped using Gelvatol mounting media.
7.8.2 Motorized stage imaging analysis
The microscope used for these studies was an automated Nikon 90i upright
fluorescence microscope equipped with 5 fluorescent channels (blue, green, red, far red
and near IR), and high N.A. plan fluor/apochromat objectives which is housed in the
Center for Biologic Imaging facilities at the University of Pittsburgh. The studies
described here were all performed using 40X objective (0.75 N.A.). Images were
collected using Nikon NIS-Elements software and a Q-imaging Retiga cooled CCD
camera. The stage was scanned using a Renishaw linear encoded microscope stage (Prior
Electronics). Neuronal counting was performed by a single trained investigator (Dr
Victor Tapias, PhD). All slides were scanned under the same conditions for
magnification, exposure time, lamp intensity and camera gain. Quantitative analysis was
performed on fluorescent images generated in 3 fluorescent colors (stained for MAP2,
TH+, and H 33342). Images were stitched with NIS-Elements, following background
subtraction and thresholding for each individual channel. Once stitched together,
colocalization and subsequent exclusion was performed on the images.
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8

Figure 8. Representative images from immunohistochemistry of aged substantia
nigra.
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7.9 Statistical Analysis
All statistical tests were performed using Graph Pad Prism 5 (Graphpad Prism,
Inc., La Jolla, CA). The data were analyzed using a two-way ANOVA (p < 0.05)
followed by post hoc comparison using an uncorrected Fisher’s LSD test.
8. RESULTS
8.1 Weight and food intake over course of the study
8.1.1 Middle-aged animals fed the control diet gained weight and weighed more than
young and old animals over the eight week study
The animals were weighed and the amount of food consumed was measured daily
to determine the effect of different diets on body weight and food intake. Young and old
mice on the control diets maintained their approximate starting weight and food intake
throughout the entire study (Fig. 9A). However, middle-aged mice on the control diet
alone gained a significant amount of weight starting at day 29 through the end of the
study (Fig. 9A). Middle-aged mice also ate significantly more at days 15, 22, 43, 50, and
57 (Fig. 9C).
Weight and food intake was also analyzed between age groups. Young mice
weighed significantly less than middle-aged or old mice throughout the duration of the
study (Fig. 9A). Moreover, middle-aged mice weighed significantly more than aged mice
over the eight-week period.
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9A

9B

9C

9D

Figure 9. Age-related changes in weight and food intake.
Results are presented as a mean ± SEM. n = 5. (A) Body weight (in grams) was
measured daily. Middle aged mice gained a significant amount of weight over an
eight week period (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 vs middle-aged
day 0). (B) Food intake was monitored daily by administration of 6g/day and weight
of food (in grams). (C)Middle-aged mice ate significantly more though out the eight
week study as compared to the beginning (*p<0.05, **p<0.01, ***p<0.001 vs middle
–aged day 0). Data were analyzed using a one-way ANOVA followed by a post hoc
comparison using a Dunnett’s test.
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8.1.2 Young animals fed the pinostilbene diet gained weight, while the middle-aged
and old animals weighed the most, over the eight-week study
In order to determine if dietary supplementation with resveratrol, pinostilbene, or
wild blueberries increased weight over the course of the study, food intake and body
weight was measured periodically. Interestingly, young animals on the pinostilbene, but
not resveratrol, diet gained a significant amount of weight, as compared to their starting
weight, starting at day 50 through the end of the study (Fig. 10A). In contrast, middleaged and old animals in the three diet groups (control, resveratrol, and pinostilbene) did
not gain or lose a significant amount of weight as compared to their starting weights (Fig.
10B and C).
The difference in weight gain between age groups was also investigated. On the
resveratrol diet, middle-aged mice weighed significantly more than young mice on days
8, 15, and 36 through the end of the study (Fig. 11A). Old animals weighed significantly
more than young and middle-aged animals on resveratrol-supplemented diet, but only
towards the end of the eight-week study (days 36-57; Fig. 11A). Middle-aged and old
mice on pinostilbene diet also weighed significantly more than young mice (days 8, 15,
and 37-57 and days 36-57, respectively; Fig. 11B).
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Figure 10. Weight changes between diet groups with age.
Results are presented as a mean ± SEM; n= 5. (A) Body weight (in grams) was
measured daily. (A)Young mice on the pinostilbene diet gained a significant amount
over weight over the course of the study as compared to the starting weight (*p<0.05).
(B) Middle aged mice did not display a significant change in weight. (C) Old mice did
not gain a significant amount of weight throughout the course of the study. Data were
analyzed using a one-way ANOVA followed by a post hoc comparison using a
Dunnett’s test.
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Food intake (g)

11A

11B

Figure 11. Dietary supplementation with resveratrol or pinostilbene does not
change food intake between age groups.
Results are presented as a mean ± SEM; n= 5. Food consumption (in grams) was
measured daily. There was no change in food consumption by either the resveratrol
(A) or pinostilbene (B) supplemented mice. Data were analyzed using a one-way
ANOVA followed by a post hoc comparison using a Dunnett’s test.
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8.3 Aged mice make more errors than young and middle-aged animals on the
challenge beam task
In the current study, age-related motor deficits were measured using two
behavioral tests. The first test, the challenge beam task was used to measure motor
coordination by examining three parameters: 1) the number of errors made, 2) steps taken
while crossing the beam, and 3) the time it takes to transverse the length of the beam.
These parameters measure motor coordination (errors) and activity (steps taken and time
to cross). Aged (22 mo) C57Bl/6 male mice made significantly more errors on the
challenge beam than young mice (2 mo; Fig. 12A). Additionally, while it was not
statistically significant, old mice made more errors than middle-aged mice (10 mo; p
value = 0.053, Fig. 12A).
In regards to number of steps taken to cross the beam, middle-aged mice take
significantly fewer steps than young mice (Fig. 12B). When analyzing the data as
errors/step rather than just the number of errors, old mice still made significantly more
errors than young mice, however the trend towards significance was lost when comparing
middle and old-aged mice (p=0.17; Fig. 12C).
Another parameter that might affect the errors made on the beam, is the time
taken to cross the beam. Although the hypothesis was that old animals would take longer
to transverse the beam, the time to cross the beam was not significantly different between
the age groups (Fig. 12D). Taken together, these data suggest that the number of steps or
the time they take to cross the beam does not affect the increase in the number of errors
made by the old animals.
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The challenge beam consists of four segments (25 cm each, 1 m total length) that
get progressively narrower (3.5 cm to 0.5 cm by 1 cm increments) as the mouse moves
towards its home cage. Therefore, we examined the number of errors the mice made on
each segment of the beam to determine if the age-related changes in motor coordination
are dependent on the width of the beam. Middle-aged and old mice made significantly
more errors than young mice on the narrowest part of the beam (Fig. 13). Young,
middle-aged, and old mice made significantly more errors on the fourth, narrowest,
segment of the beam than the first segment (Fig. 13). Old mice make significantly more
errors on the fourth segment of the beam than either the second or third segments of the
challenge beam.
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12A

12B

12D

12C

Figure 12. Age-related changes in motor coordination as measured by the
challenge beam in C57Bl/6 male mice.
Results are presented as mean ± SEM. n = 37-40. C57Bl/6 male mice display agerelated motor deficts as measured by the challenge beam task. (A) Old mice made
significantly more errors than young mice (**p < 0.05) and more errors than middleaged mice (p=0.053). (B) Middle-aged mice took significantly less steps while
traversing the challenge beam than young mice. (C) Old mice make significantly
more errors on the challenge beam than young mice (***p<0.0001). (D) Time to
traverse the beam was not different between the different age groups. Data was
analyzed using a two-way ANOVA followed by a post hoc analysis with an
uncorrected Fisher’s LSD test.

66

13

10

****

8
6

**

Segment 1
Segment 2
Segment 3
Segment 4

4
2
0

Figure 13. Age-related increases in the number of errors of aged C57Bl/6 male
mice on the challenge beam task.
Results are presented as mean ± SEM. n = 37-40. C57Bl/6 male mice display agerelated motor deficits as measured by the challenge beam task. The beam becomes
progressively narrower as the mice traverse to their home cage. Middle-aged and old
mice make significantly more errors on the narrowest segment of the beam than
young mice (**p<0.01 and ****p < 0.0001). Old mice make significantly more
errors than middle-aged mice on the fourth segment of the beam (****p<0.0001).
Data was analyzed using a two-way ANOVA followed by a post hoc analysis with
an uncorrected Fisher’s LSD test.
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8.4 Dietary supplementation with resveratrol or WBB alleviate age-related motor
deficits
In order to determine if four weeks of dietary supplementation would improve
motor coordination on the challenge beam task, mice were retested on the challenge
beam. Similar to the results obtained before the start of the diets, old mice on control diet
made significantly more errors than young or middle-aged mice at the four week time
point (Fig. 14). While dietary supplementation with wild blueberry powder did not alter
the number of errors made by young or middle-aged animals, this diet significantly
decreased the number of errors made by the old mice as compared to old mice fed control
diet (Fig. 14A). Moreover, old mice fed resveratrol and wild blueberry diets, no longer
made significantly more errors than the young or middle-aged animals in the same
groups. In contrast to resveratrol, pinostilbene supplementation did not alter the number
of errors made by any age group (Fig. 14A). After eight weeks of dietary
supplementation, old mice still made significantly more errors than young or middle-aged
mice on the control diet (Fig. 15A). However, middle-aged and old mice on a
pinostilbene supplemented diet made significantly more errors than young mice (Fig.
15A).
Similar to the comparison of the control only groups, the narrowest segment
(segment 4) of the beam was analyzed after four weeks to determine if dietary
supplementation would improve fine motor control. Aged mice made more errors than
young or middle-aged mice (14B). Interestingly, old mice on the wild blueberry
supplemented diet made significantly less errors than their old counterparts on control
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diet (14B). Resveratrol and pinostilbene supplemented diets did not improve motor
coordination on the narrowest segment of the beam. After eight weeks, old animals still
make more errors on the narrowest, most difficult, segment of the beam as compared to
young animals on the control diet (15B). However, old animals on the resveratrolsupplemented diet now make significantly more errors than young mice on the resveratrol
diet (15B). While at four weeks aged mice on the resveratrol diet make an average of 3.6
errors/segment 4 by eight weeks they are making 4.15 errors/segment 4. Also at eight
weeks wild blueberry supplementation no longer improves motor coordination on the
narrowest segment of the beam.
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14A

14B

Figure 14. Wild blueberry dietary supplementation attenuates age-related motor
deficits after four weeks.
Results are presented as mean ± SEM. n = 5-10. Mice were retested on the challenge
beam task after 4 weeks. (A) Aged mice made significantly more errors than young
(**p<0.01) and middle-aged (^p<0.05) mice. Old mice on wild blueberry diet made
significantly less errors than old control mice (***p<0.001). (B) Wild blueberry
supplementation improves motor coordination in aged mice on the fourth and most
difficult segment of the beam (p<0.05 vs old control). Data was analyzed using a twoway ANOVA followed by a post hoc analysis with an uncorrected Fisher’s LSD test.
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15A

15B

Figure 15. Old mice continue to make more errors on the challenge beam task after
eight weeks on natural supplemented diets.
Results are presented as mean ± SEM. n = 5-10. Mice were retested on the challenge
beam task after 8 weeks. (A) After 8 weeks, there is no difference in errors between
middle-aged and old mice. However, old mice made more errors than young mice
(*p<0.05). (B) Old mice make significantly more errors on the most narrow segment of
the beam (*p<0.05 vs young controls; ^p<0.05 vs middle aged pinostilbene). Data was
analyzed using a two-way ANOVA followed by a post hoc analysis with an uncorrected
Fisher’s LSD test.
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8.5 Age related changes with spontaneous activity
To determine whether age had an effect on spontaneous activity, each animal was
measured at the end of the eight week study by placing each mouse in a Plexiglas
cylinder and videotaping their movements for three minutes. The videotapes were then
analyzed for rearing behavior, forelimb and hind-limb steps, and time the mice spent
grooming by an investigator blind to the age and treatment group. Age did not alter the
average number of rears (16A), the average number of forelimb steps (16B), or the
amount of time that each mouse spent grooming (16D). However, old mice made
significantly less hind-limb steps than young mice (16C).
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16A

16B

16C

16D

Figure 16. Hindlimb stepping is decreased in aged C57Bl/6 male mice.
Spontaneous activity was measured by counting rears, forelimb and hind-limb steps,
and grooming over three minutes. Age did not alter the amount of rears (A) or
forelimb steps (B) or time spent grooming (D) made by the mice. However, old mice
made significantly less hind-limb steps than young animals (C, *p<0.05vs young).
Data was analyzed using a one-way ANOVA followed by post hoc analysis using an
uncorrected Fisher’s LSD test.
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8.6 Pinostilbene diet increases rearing activity in middle-aged and old mice
In order to determine in dietary supplementation with natural products would alter
exploratory or spontaneous activity, each animal was measured at the end of the eightweek study by placing each mouse in a Plexiglas cylinder and videotaping their
movements for three minutes. The videotapes were then analyzed for rearing behavior,
forelimb and hind-limb steps, and time the mice spent grooming by an investigator blind
to the age and treatment group. Pinostilbene supplementation significantly increased the
number of rears made by middle-aged and old animals (Fig. 17A). Moreover, old animals
treated with pinostilbene made more rearing movements than old control animals (Fig.
17A). Neither resveratrol nor wild blueberry powder supplementation significantly
increased the number of rears made by young, middle, or old aged animals. Forelimb and
hind-limb steps and time spent grooming were not changed with age or dietary
supplementation of resveratrol, pinostilbene, or wild blueberry powder (Fig. 17).

74

17A

17B

17C

17D

Figure 17. Pinostilbene diet increases rearing activity in middle-aged and old
mice.
Results are presented as mean ± SEM, n = 5-10. Spontaneous activity was measured
by counting rears, forelimb and hind-limb steps, and grooming. Age did not alter the
amount of rears (A) or forelimb steps (B) or time spent grooming (D) made by the
mice. (A) Pinostilbene diet increased rearing significantly from young pinostilbene
(*p<0.05) and old control (^p<0.05). Neither age nor dietary supplementation altered
forelimb steps (B) or time spent grooming (D). However, pinostilbene diet decreased
hind-limb steps in young mice (**p<0.05). Data were analyzed using a two-way
ANOVA with a post hoc analysis with an uncorrected Fisher’s LSD test.
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8.7 Resveratrol and pinostilbene are present in the hippocampus after eight weeks
of dietary supplementation
To determine if pinostilbene or resveratrol penetrated the blood brain barrier the
hippocampi of each group of mice were analyzed by GC-MS after the eight weeks of
dietary supplementation. Resveratrol was detected in trace amounts in both middle-aged
and old animals; however it was not detected in young animals (Table 2). Pinostilbene
was present in the hippocampus of all the age groups (Table 2). The amount of
pinostilbene found in middle and old-aged animals was double the amount found in
young animals.
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Sample description

Pinostilbene

Resveratrol

(ng/mg tissue)

(ng/mg tissue)

Young

0.0365

NA

Middle

0.0772

NA

Old

0.0776

NA

Young

NA

nd

Middle

NA

trace

Old

NA

trace

Table 2. Pinostilbene and resveratrol penetrate the blood-brain barrier in aged
animals.
Results are presented as ng/mg fresh tissue, n = 2. Hippocampi were analyzed by
GC-MS for the presence of pinostilbene and resveratrol.
NA = not applicable; pinostilbene or resveratrol was not analyzed
nd = not detected
trace = peaks are below limit of quantitation.
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8.8 DA and DA metabolite levels and TH and DAT expression in the striatum are
not altered with age
In order to determine if the amount of striatal dopamine system was altered with
age, HPLC was used to measure DA and metabolite (DOPAC and HVA) content in the
striatum of young, middle-aged, and old animals. There was not an age-related change in
DA or metabolite content in the striatum (Fig. 18). Tyrosine hydroxylase and DAT in the
striatum were analyzed by Western blot. Similar to DA and DA metabolite levels, TH
and DAT expressions were unchanged with age (Fig. 18A and B).
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18

Figure 18. DA, DOPAC and HVA levels are unchanged with age.
Results are presented as mean ± SEM, n=7. Striatal DA and metabolites
were unchanged with age in C57Bl/6 male mice. Data were analyzed using a
two-way ANOVA with a post hoc analysis with an uncorrected Fisher’s LSD
test.
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8.9 DA and DA metabolite levels and TH and DAT expression in the striatum are
not altered following 8 weeks of dietary supplementation with pinostilbene or wild
blueberry powder; however, resveratrol decreases striatal DA
To determine if dietary supplementation with resveratrol, pinostilbene, or wild
blueberries altered the striatal dopamine neuronal system, HPLC was used to measure
DA and DA metabolite (DOPAC and HVA) content in the striatum of young, middleaged, and old animals after eight weeks. DA content was decreased in the striatum of old
mice fed the resveratrol-supplemented diet (Fig. 19C). In contrast, there was not a change
in DA or DA metabolite content in the striatum in any age group fed a pinostilbene or
wild blueberry powder supplemented diet (Fig. 19). Striatal TH and DAT were analyzed
by Western blot. Dietary supplementation with resveratrol, pinostilbene, or wild
blueberry powder did not alter TH or DAT expression in the striatum (Fig. 20).
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19A

19B

19C

Figure 19. Resveratrol decreases DA in the striatum in aged mice.
Results are presented as mean ± SEM, n=7. In aged mice, resveratrol significantly
decreased striatal DA levels. However DOPAC and HVA were unchanged. Data were
analyzed using a two-way ANOVA with a post hoc analysis with an uncorrected
Fisher’s LSD test
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20A

20B

Figure 20. Age and dietary supplementation do not alter striatal TH or DAT.
Results are presented as mean ± SEM. (A) Tyrosine hydroxylase (TH), the rate
limiting enzyme in DA synthesis, was unchanged with age or with dietary
supplementation with resveratrol, pinostilbene or wild blueberries (B) The dopamine
transporter, DAT, was unchanged with age. Dietary supplementation with resveratrol,
pinostilbene or wild blueberries did not alter striatal DAT. Data were analyzed using
an unpaired t-test with a 95% confidence interval.
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8.10 The number of TH+ neurons in the substantia nigra is not altered with age
To assess whether or not age decreased the number of DA neurons in the
substantia nigra, immunohistochemistry of the hindbrain was performed to measure the
number of TH+ neurons in the striatum. Hindbrain slices were probed with TH and MAP2 antibodies and nuclei were stained with Hoechst dye to quantify the number of DA
neurons, the number of neurons in general, and the total number of cells, respectively.
Our data suggests there was no change in the number of TH+ neurons in the substantia
nigra with age (Fig. 21). In future studies, the total number of neurons and cells will be
quantified to determine if there are age-related changes in these parameters.
8.11 Dietary supplementation with pinostilbene or wild blueberries increases the
number of TH+ neurons visualized in the substantia nigra
To assess whether or not dietary supplementation with resveratrol, pinostilbene,
or wild blueberries altered the number of DA neurons in the substantia nigra,
immunohistochemistry was performed on the hindbrain to measure TH+ neurons.
Treatment with pinostilbene or wild blueberries, but not resveratrol, increased the number
of TH+ neurons visualized in the substantia nigra in old animals (Fig. 22).
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21

Figure 21. Age does not alter the amount of TH+ neurons in the
substantia nigra.
Results are presented as mean ± SEM, n=5. The number of TH+ neurons
were measured by fluorescent microscopy. Age did not alter the amount
of TH+ neurons in the SN. Data were analyzed using a two-way ANOVA
with a post hoc analysis with Fisher’s LSD test.
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22A

22B

22C

Figure 22. Wild blueberry and pinostilbene supplementation increase the
amount of TH+ neurons in the substantia nigra.
Results are presented as mean ± SEM, n=5. Dietary supplementation with resveratrol,
pinostilbene, or wild belueberries in young (A) or middle-aged (B) mice. (C)
Pinostilbene and wild blueberries significantly increased TH+ neurons in the SN of
aged mice (*p<0.05). Data were analyzed using a two-way ANOVA with a post hoc
analysis with an uncorrected Fisher’s LSD test.
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9. DISCUSSION
A number of deficits, both behavioral and neurological, have been shown to
increase with age. In this study, we used a mouse model of aging to investigate agerelated alterations in the nigrostriatal DA system and motor coordination. Additionally,
we examined the effect of natural supplements on motor function and, subsequently, the
DA neuronal system.
While relatively little research has been done in animal models to examine
changes occurring due to normal aging, the literature that does exist consistently
demonstrates a decline in spontaneous motor activity and motor coordination in rodents
(Cantuti-Castelvetri et al., 2003; Boger et al., 2006; Colebrook et al., 2006). Currently,
most aging studies do not include a middle age group. It is the recommendation of the
NIA that middle-aged animals be included in aging animals studies as any changes that
occur may begin at mid-life and interventions may be more effective if started during this
time period (JEC, personal communication). Therefore, the current study sought to assess
age-related differences in young, middle-aged, and old C57BL/6 male mice using the
challenge beam and cylinder behavioral tests to measure motor coordination and
spontaneous activity, respectively.
Since the weight of the animals may affect their ability to cross the challenge
beam, such that a significant weight gain could cause a decrease in mobility, body
weights and food intake were recorded over the eight-week testing period. Metabolism is
known to slow with age, in part, due to an age-related increase in fat mass and a
concomitant decrease in lean muscle (Nassis and Geladas, 2003; Hughes et al., 2004;
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Newman et al., 2005). Therefore, the current hypothesis was that the old animals would
gain weight and weigh significantly more that the young and middle-aged animals during
the course of our study. Surprisingly, the middle-aged, but not the old, animals gained a
significant amount of weight throughout the study (Fig. 9A). The increase in body weight
in middle-aged animals may be accounted for by the increased food consumption (Fig.
9C). Also, middle-aged mice weighed more than old mice throughout the eight week
study. Because the challenge beam test is a beam that gets progressively narrower; weight
may affect the amount of errors made by the animals. A different task, such as gait
analysis or wire grasping may be more appropriate if weight is an issue. However, the
amount of errors per weight was examined and even after taking weight into
consideration, aged mice made significantly more errors on the challenge beam task, as
compared to young and middle-aged mice in our study (data not shown). Weight may
also alter the measures of spontaneous activity, such as time and steps taken to cross the
beam, because larger animals may be more sedentary, and thereby slower, than smaller
animals. However, as there was not a difference in spontaneous activity as noted by the
number of steps or time taken to cross the beam, it appears that weight was not a
confounding factor in our studies.
Also the number of steps that mice made while crossing the beam was examined.
Steps are an important parameter because the number of steps taken by each mouse may
contribute to the number of errors made by the animals on the challenge beam. In this
study, young and old animals took the same number of steps while middle-aged mice
took fewer steps than aged mice. Another parameter measured using the challenge beam
task is the amount of time it takes the mouse to traverse the beam. Surprisingly, the mean
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time that it took each group to cross the beam was not significantly different between the
three age groups. Therefore, as the data did not note a decrease in the number of errors
that correlated with the steps or time data, this concludes that the challenge beam test data
reflects age-related motor decline unaffected by these other parameters.
The challenge beam gets progressively narrower as the mouse moves towards the
home cage, getting more challenging for the mouse. Therefore, the errors per segment of
beam were analyzed to show where the mice made the most errors while traversing the
beam. Middle and old aged mice made significantly more errors than young mice on the
fourth beam segment, the narrowest portion of the beam. This may indicate the middleaged and old mice lose more fine motor control and/or balance, while young mice
maintain those motor functions.
To analyze whether the challenge beam could be used for a longer period of time,
we retested the mice after four and eight weeks on the supplemented diets in our animal
facility. Aged mice made significantly more errors than young and middle-aged mice at
four weeks. However, by eight weeks the difference between middle-aged and old mice
was no longer significant. This is due to the fact that middle-aged mice made more errors
at week eight than at week four ( =5.6

=3.8, respectively), while aged mice make

approximately the same number of errors at weeks four and eight ( =6.9 and

=7.0,

respectively). This increase in number of errors in the middle-aged group suggests that a
decline in motor coordination may begin to occur at 12 months. As mentioned earlier,
until recently, most studies using aged animals did not include a middle-aged group. Our
data underscore the importance of including the middle-aged group as behavioral changes
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may begin at this age.
Similar to the data at the beginning of the study and at four weeks, aged mice fed
control diet still make more errors than young mice at eight weeks (p<0.05, Fig. 15A).
These data suggest that the challenge beam test is an appropriate behavioral task for the
measurement of age-related loss of motor coordination up to at least eight weeks
following the first test. Therefore, this behavioral test was used to study the effect of 8
weeks of dietary supplementation with resveratrol, pinostilbene, and wild blueberry
powder on motor coordination using 4 and 8 weeks as time points for testing.
To examine the effect of diet on body weight and food intake, animal weights and
the amount of food intake was measured daily in the resveratrol, pinostilbene and WBB
supplemented groups as we did for the control groups. A review of the literature shows
that resveratrol supplemented diets suppresses body fat accumulation via fat oxidation,
carbohydrate oxidation, or protein oxidation in rodents (Kim et al., 2011; Gomex-Zorita,
2012; Nagao et al., 2013). Therefore, the hypothesis was that animals fed the resveratrol
diet might lose, rather than gain, weight. In support of this hypothesis, middle-aged and
old animals did not gain a significant amount of weight on resveratrol or pinostilbene
diet, as opposed to the same age groups on the control diet (10B). Surprisingly, young
mice on the pinostilbene, but not resveratrol, diet gained a significant amount of weight
by the end of the study as compared to their starting weight (10A). With an increase in
weight in the young pinostilbene supplemented group, the hypothesis was that this group
also increased food consumption; however, food intake between the different diets did
not change. No other groups have measured dietary intake changes with resveratrol or
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pinostilbene and nothing has been reported about the effect of pinostilbene on metabolic
rate. Therefore, although this data suggests that pinostilbene decreased basal metabolism
in the young animals, the current data cannot make this conclusion without further
studies.
After four weeks of dietary supplementation with resveratrol, old animals made
fewer errors than old mice on control diet (14A). Moreover, there was no longer a
significant difference in the number of errors between young, middle-aged, and old mice
fed the resveratrol diet, indicating that dietary resveratrol may attenuate age-related motor
deficits. In contrast to resveratrol, pinostilbene had no effect on motor function. However,
similar to results with resveratrol, wild blueberry powder supplementation significantly
decreased the amount of errors made by old animals, when compared to the old control
group and there was no longer significance between age groups (14B). Concurrently,
after four weeks on a wild blueberry supplemented diet, aged animals make significantly
less errors as compared to their aged counterparts (14B). These data suggest that
resveratrol and wild blueberry diets decrease age-related motor deficits, in as little as four
weeks. In accordance with this data, Galli and colleagues (2002) showed that 2% wild
blueberry powder dietary supplementation increased motor performance on the rod walk
task and accelerating rotorod and improved cognitive memory as measured by the Morris
water maze in Fisher 344 rats. Pearson and colleagues (2008) also showed that
resveratrol-supplemented diet improved performance on the accelerating rotorod in
C57Bl/6 mice. This is the first study to examine the effect of pinostilbene on motor
coordination and to compare the effect of isolated compounds with a whole fruit on agerelated motor decline.
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At the eight-week time point, old mice continue to make significantly more errors
than young mice on the challenge beam task (15A). However, the difference in errors
made by aged mice on the control diet and aged mice on the wild blueberry supplemented
diet is no longer significantly different (15A). Aged mice make approximately the same
average number of errors between weeks four and eight =6.8

=7.0, respectively).

However, aged mice on the wild blueberry supplemented diet have an increase in the
average amount of errors from weeks four to eight ( =3.1

=5.5, respectively). The

rise in the average number of errors in the aged wild blueberry supplemented mice may
account for the loss of protection from age-related motor deficits.
Spontaneous activity, as measured by the cylinder test, was also examined in this
study as a measure of exploratory behavior. This test can be used to analyze four
parameters for exploration as described above. There was not a significant difference in
the average amount of rears, forelimb steps, or time spent grooming by the three different
ages fed control diet (16A, C, and D). Aged mice did take significantly less hind-limb
steps as compared to the young mice (16C). Interestingly, pinostilbene supplementation
increased the amount of rears made by middle-aged and old mice, as compared to young
mice on the pinostilbene diet (17A). Young mice on the pinostilbene supplemented diet
made significantly less hind-limb steps than their young control counterparts (17C). As
weight gain is often accompanied with a sedentary lifestyle, this result may be due to the
fact that young mice gained a significant amount of weight towards the end of the study.
Alternatively, this result may be due to the fact that these animals spent more time on
their hind legs rearing on the side of the cylinder rather than exploring on the floor of the
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cylinder. None of the other parameters showed a significant difference either in the
control or treatment groups.
Motor coordination is largely controlled by the dopamine system (Pijnenburg and
Van Rossum, 1973; Jackson et al., 1975; Costall and Naylor, 1975; Costall et al, 1976).
Loss of dopamine neurons in the substantia nigra and striatum are seen with age and in
Parkinson’s disease with a concurrent loss of motor coordination (McGeer et al., 1977;
Fearnley and Lees, 1991). Interestingly, resveratrol and wild blueberries have been
shown to protect neurons in vivo and in vitro through a variety of antioxidant signaling
mechanisms. Therefore, the antioxidant properties of these compounds may decrease
oxidative stress and thereby protect DA neuronal function in the striatum or substantia
nigra to improve motor coordination. For these reasons, after the conclusion of the
behavioral portion of this study, the DA neuronal system was analyzed to determine
whether age-related motor deficits were associated with a loss of DA or DA neurons.
Before examining the effect of the natural products on the DA system, there was a
need to determine if the natural compounds were able to penetrate the blood brain barrier.
To this end, the hippocampus from each age group was analyzed for the presence of
pinostilbene or resveratrol. Resveratrol was found in trace amounts in the hippocampi of
middle-aged and old animals; however it was not detected in the hippocampus of young
animals (Table 2). Pinostilbene was found at detectable levels in young, middle-aged, and
old animals. Twice the amount of pinostilbene was detected in the hippocampi of middleaged and old as compared to the young animals (Table 2). As seen with the resveratrol
animals, young mice showed less penetration of each of the compounds. The lack of
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resveratrol and the lower levels of pinostilbene in the hippocampi of the young animals
may be due to the fact that resveratrol and pinostilbene were rapidly metabolized in the
periphery in the young animals. Also, while this lack of or decreased absorption across
the blood brain barrier in the young animals may be due to rapid metabolism of the
compounds, it may also be due to differences in the integrity of the blood brain barrier in
the different age groups. Farrall and Wardlaw (2009) have shown that there is a
breakdown of the BBB integrity with age. Therefore, the breakdown of this barrier, while
detrimental for toxic insults to the brain, may have led to an increased absorption of these
two compounds in middle-aged and old animals.
As previously mentioned changes in the DA system with age are controversial
and strain specific. It has previously been reported that DA and DA metabolite levels, as
well as TH and DAT expression were unchanged with age in the striatum (Allen et al.,
2011). Similarly, in a separate group of animals used in this study, there were no changes
in DA or DA metabolites (DOPAC and HVA) with age in the striatum (Fig. 18). TH and
DAT expression were also unchanged with age. Surprisingly, resveratrol treatment
decreased the amount of DA in the striatum of aged animals (Fig. 19). While resveratrol
has antioxidant properties, it has also been shown to have pro-oxidant activities (Ahmad
et al., 2003; de la Lastra and Villegas, 2007). DA is quickly oxidized once it is released
into the synaptic cleft; therefore, an increase in a pro-oxidant compound, such as
resveratrol, may further decrease DA content in the striatum.
As with the previous study, there was no change in TH or DAT expression in the
striatum of animals in any of the treatment groups (Fig. 20). In contrast, in humans, it has
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been reported that there is a loss of DA neurons with age (McGeer et al., 1977; Fearnley
and Lees, 1991). Other groups have reported a loss of TH, indicating a loss of DA
neurons and/or projections, with age in monkeys (Emborg et al., 1998). Moreover, a loss
of DAT expression with age has been noted in monkeys (Yue et al., 2012) and humans
(Emborg et al., 1998; Troiano et al., 2010). Therefore, as there were not alterations in TH
or DAT these DA neuronal markers with age may be species specific.
Age-related decreases in the expression of the D1 (Henry et al., 1987; Wang et al.,
1998) and D2 (Roth and Joseph, 1994; Volkow et al., 1998) receptors have also been
noted in rodents and humans. Therefore, future studies will examine D1 and D2 receptor
expression in our aging mouse model. Others have shown that in addition to changes in
the striatal DA system, there are alterations at the level of the substantia nigra, including
a loss of DA neurons, which may affect motor function (Fleming et al., 2006). Therefore,
this study examined the number of DA neurons in the SN across ages and treatment
groups using immunostaining to quantify the number of TH+ neurons. Analysis of
hindbrain sections containing the SN indicated that there was not a decrease in the
number of TH+ neurons with age (Fig. 21). In young and middle-aged animals, dietary
supplementation with resveratrol, pinostilbene, or wild blueberry powder did not alter the
number of TH+ neurons (Fig. 22A/B). However, in the aged group, dietary
supplementation with pinostilbene or wild blueberry powder increased the number of
TH+ neurons visualized (Fig. 22C). One explanation for this increase is that DA neurons
become quiescent with age, losing expression of TH as a phenotypic marker, and wild
blueberry powder or pinostilbene treatment returns the neurons to a more functional state
restoring TH levels. Another possibility is that there is an increase in oxidative stress in
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the SN in this aging mouse model and these antioxidant compounds restore homeostasis
and allow these cells to function normally. The increase in TH+ neurons may be an
indication of how wild blueberries alleviate age-related motor deficits. Similar results
were seen in the SN of aged animals treated with pinostilbene; however pinostilbene did
not change age-related motor deficits. Although resveratrol did slightly decrecrease agerelated motor deficits, there was not an increase in TH+ neurons in the SN with
resveratrol dietary supplementation; this may be due to the limited penetration of
resveratrol in the brain. Future studies will explore these hypotheses.
In conclusion, aged C57Bl/6 male mice make significantly more errors on the
challenge beam test as compared to young mice without a significant contribution of
weight, food intake, average number of steps, or time to cross the beam. These data
suggest that C57Bl/6 male mice and the challenge beam test are a good model and
behavioral measurement of age-related motor deficits, respectively. Moreover, these data
suggest that age-related motor deficits may not be due to a loss of DA or DA metabolite
content in the striatum, but rather, a loss of functional DA neurons in the SN. Finally,
dietary supplementation with resveratrol or wild blueberry powder alleviated the motor
deficits observed on the challenge beam test in as few as four weeks and pinostilbene diet
increased the spontaneous activity of the middle-aged and old animals. Interestingly,
resveratrol diet had no effect on the DA parameters measured, while pinostilbene and
wild blueberry supplemented diet increased the number of TH+ neurons visualized in the
SN. Although the mechanism of protection against motor decline with age is not entirely
clear and more studies need to be performed, the data thus far suggest that natural
products may be effective therapies for motor deficits that are associated with aging.
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Chapter 3
The effect of isolated natural products on dopamine-induced oxidative stress in SHSY5Y cells
10. RATIONALE AND HYPOTHESIS
10.1 RATIONALE
Natural products have been shown to alleviate motor deficits associated with age
and neurodegenerative diseases (Joseph et al., 1999; 2003) and in our own previous
studies, we showed that dietary supplementation with resveratrol or wild blueberries
decreased age-related motor deficits. Therefore, we sought to investigate the possible
mechanisms by which these natural products may produce the beneficial effects seen in
vivo.
As mentioned previously, oxidative stress is known to increase with age in the
brain (Harman, 1992; Ames et al., 1993; Joseph et al., 1996). A concurrent decrease in
antioxidant mechanisms causes an environment that may be toxic to neurons and lead to
neurodegeneration. DA neurons are especially vulnerable to oxidative stress, possibly due
to the increased exposure to ROS produced by the by-products of DA metabolism. Many
cell signaling pathways are activated in response to oxidative stress; however, this
research is specifically focused on the MAPK pathways, ERK1/2 and ERK5. ERK1/2
activation is thought to play a critical role in cell survival in response to oxidative stress
in rat PC12 cells and primary cortical neurons (Guyton et al., 1996; Crossthwaite et al.,
2002). Moreover, ERK1/2 activation protects against hypoxia-induced cell death in
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primary cortical cultures (Wang et al., 2001) and H2O2-mediated cell death in primary
striatal cell cultures (Crossthwaite et al., 2002).
Interestingly, wild blueberry treatment has been shown to activate ERK1/2 in
primary hippocampal cells that were exposed to DA (Joseph et al., 2010). However,
Vuong and colleagues (2010) found that inhibition of ERK1/2 protected cells from H2O2induced cell death in N2A neuroblastoma cell culture. Resveratrol research is divided
when it comes to ERK signaling. Some groups show resveratrol-mediated protection
from oxidative stress is through activation of ERK1/2 (Maher et al., 2011; Simao et al.,
2012) and others find that inhibition of ERK1/2 is protective (Arun et al., 2013).
In the current study, the dopaminergic-like SH-SH5Y cells were used as an in
vitro model of DA neurons and DA treatment to produce oxidative stress to examine the
effect of resveratrol, pinostilbene, and wild blueberry powder on DA-induced toxicity.
Furthermore, the effect of these compounds on ERK activation and explored a role for
the MAPK pathways in protection from oxidative stress were examined.
10.2 HYPOTHESIS
Natural products protect against dopamine-induced oxidative stress via activation
of the ERK1/2 and/or ERK5 signaling pathways
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11. MATERIALS AND METHODS
11.1 SH-SY5Y Cell Culture
SH-SY5Y (catalog # CRL- 2266; ATCC, Manassas, VA) cells were grown on
10cm cell culture plates (Sarstedt, Newton, NC) in Dulbecco’s Modified Eagle’s Medium
(DMEM; Gibco, Carlsbad, CA) with 10% heat-inactivated fetal bovine serum (FBS;
Atlanta Biological, Lawrenceville, GA), 0.1% Uridine (Sigma, St. Louis, MO), 0.1%
Pyruvate (Sigma), and 1% penicillin/streptomycin (Gibco). Cells were maintained at
37°C with 5% CO2. After cells reached 85-90% confluency in 10cm plates, they were
incubated with 1.5mL TrypLE (catalog # 12604; Invitrogen; Grand Island, NY) and
plated at a density of 1.5 x 104 cells per well for 96 well plates and 6.0 x 106 cells per
35mm plate.
11.2 Resveratrol and Analogues
The structures of resveratrol and analogs are shown in Figure 2. Resveratrol and
the analogs were gifts from Dr. Agnes Rimando at the USDA facility in University,
Mississippi. For further derivations, see Joseph et al., 2008.
11.2 Treatment of Cell Cultures
SH-SY5Y cells were plated in 96-well plates (Becton Dickinson, Franklin Lakes,
NJ), 35mm plates (Becton Dickinson) and 60 mm culture plates (Sarstedt, Newton, NC)
and allowed to grow for 48 hrs.
11.2.1 Resveratrol or pinostilbene treatment
98

Resveratrol was purchased from a commercial source (TCI America, Portland,
OR). Pinostilbene was a gift from Dr. Agnes Rimando. A stock solution of each
compound was dissolved in DMSO (Sigma Aldrich). For each treatment, a fresh dilution
of resveratrol or pinostilbene was made in serum-free media. SH-SY5Y cells were treated
with 1, 3 or 5µM resveratrol or pinostilbene. SH-SY5Y cells were treated with DMSO
(2µL, the total volume of resveratrol or pinostilbene treatment) as a vehicle control.
11.2.2 Dopamine treatment
Dopamine (Sigma Aldrich, cat # H8502, lot # 1381581) was dissolved in sterile
water to an initial concentration of 100mM. The dopamine solution was further diluted
with sterile water to treat. Treatment with dopamine (50, 100 or 200M) followed 30 min
after resveratrol or pinostilbene treatment and lasted for 24 hrs. SH-SY5Y cells were also
treated with H2O alone as a vehicle control.
11.2.3 U0126 treatment
U0126 (Cell Signaling, cat # 9903, lot #11), the ERK1/2 specific inhibitor, was
dissolved in DMSO. The initial concentration was 10mM. U0126 was further diluted to
1mM in DMSO for treatment of SH-SY5Y cells. Cells were treated with U0126 (10µM)
1 hr prior to resveratrol treatment (90 min prior to dopamine treatment). SH-SY5Y cells
were also treated with DMSO (2µL; the total volume of U0126 treatment) as a vehicle
control.
11.3 Cell Death Assays
11.3.1 Cell Titer Glo®
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Following treatment in 96 well plates, SH-SY5Y cells were analyzed by Cell
Titer Glo® (Promega, Madison, WI) for cell viability at 24 and 48 hours. The Cell Titer
Glo® reagent uses luciferin, which gives off a luminescent signal after interacting with
ATP, Mg2+, and mono-oxygen (Promega Technical Bulletin, 2012). SH-SY5Y cells were
removed from the 5% CO2 incubator and equilibrated to room temperature for 30 min.
From each well, 150µL of media was removed, leaving a final volume of 50µL. Then
50µL of Cell-Titer Glo reagent was added and the contents were vigorously mixed for 2
min on a shaker. The plates were incubated for 10 min at room temperature. Following
incubation, 50µL of cells and Cell-Titer Glo® reagent was transferred to a black 96-well
microplate. Luminescence was recorded using a microplate reader (Perkin Elmer,
Waltham, MA).
11.3.2 Hoechst Staining
SH-SY5Y cells were plated into 96 well plates (Midi-Sci). Cells were pre-treated
with 1 or 5µM resveratrol or pinostilbene. After 30 min pretreatment, 0, 50 or 100µM
DA was added to each respective well for 24 hours. Media was removed from the wells
and the cells were fixed with 500µL of 4% paraformeldehyde/4% sucrose in PBS for
15min. Fix was removed and cells were was three times with 1XPBS/0.02%NaN3. After
the washes, 500µL of Hoechst stain (bis-benzimide, Sigma) was added to each well.
Hoechst dye is cell membrane permeable and binds to double stranded DNA. After 20
min, the Hoechst stain was removed and the cells were stored in 1XPBS/0.02%NaN3 at
4ºC until they were visualized. Four pictures of each well was taken at 12, 3, 6, and

100

9’o’clock on an epifluorescent microscope (EVOSfl, Advanced Microscopy Group,
Bothell, WA). Each picture was then counted for live and dead cells.
11.4 Western Blot Analysis
SH-SY5Y cells were plated in 60mm plates and treated with resveratrol (RV1;
5µM) or pinostilbene (RV2; 5µM) over a time-course (15 min – 48 hours). The cells
were washed with ice-cold 1XPBS and then lysed (1% Triton X-100 buffer containing
20mM Tris (pH 6.8), 137mM NaCl, 25mM beta glycerophosphate, 2mM NaPPi, 2mM
EDTA, 1mM Na3VO4, 10% glycerol, 5µg/mL leupeptin, 5µg/mL aprotinin, 2mM
benzamidine, 0.5mM DTT, and 1mM PMSF) at the times stated above. The lysates were
then centrifuged at 10,000 rpm for 10 min at 4°C. Determination of protein content in the
supernatant was done using a Bradford assay (Biorad, Hercules, CA).
Equal amounts of protein (30µg) from each treatment were separated on 8% SDS
gels and transferred for 1h at 100 volts to nitrocellulose membrane (Li-Cor Biosciences,
Lincoln, NE) for Western blot analysis. Membranes were blocked in casein blocking
buffer (Li-Cor Biosciences) for 1 hr and then incubated overnight at 4°C in primary
antibody: mouse anti-ERK1/2 (1:1000, catalog # 9107; Cell Signaling Technology),
rabbit anti- phospho-ERK1/2 (1:1000, catalog # 9101; Cell Signaling Technology) rabbit
anti-ERK5 (1:1000, Sigma), rabbit anti-phospho-ERK5 (1:1000, catalog # 3371; Cell
Signaling Technology) or mouse anti-GAPDH (1:1000, Millipore). Blots were washed
with 1XPBS/0.1% Tween for 20 min. Binding was visualized with infrared secondary
antibodies fluorescing at 700 nm (goat anti-rabbit for phospho-ERK1/2, ERK5, and
phospho-ERK5) or 800 nm goat anti-mouse for phospho-ERK1/2 and GAPDH; Odyssey
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Imaging; LI-Cor Biosciences) applied for 1 hr at room temperature (1:10,000 in casein
blocking solution; Li-Cor Biosciences). Blots were scanned on an Odyssey Imager and
quantified with Odyssey software, using background subtraction above and below each
band. Grayscale images were used for quantification, and the images were pseudocolored red (700 nm) and green (800 nm) to delineate anti-rabbit and anti-mouse
antibodies using distinct fluorescent wavelengths.
11.5 Statistical Analysis
All statistical tests were performed using Graph Pad Prism 5 (GraphPad Software,
Inc., La Jolla, CA). Grubb’s test (GraphPad Software, Inc., La Jolla, CA) was used to
determine if there were any significant outliers (p<0.05) in the data. The data were
analyzed using a one-way or two-way ANOVA (p<0.05) followed by post hoc
comparison using an uncorrected Fisher’s LSD test.
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12. RESULTS
12.1 Resveratrol and resveratrol analogs protect against DA-induced oxidative
stress
In order to determine if dopamine was an appropriate toxin SH-SY5Y cells were
treated with increasing concentrations of DA (50, 100, or 200µM). DA treatment
significantly decreased SH-SY5Y cell viability in a concentration dependent manner as
measured by loss of ATP (data not shown). For this experiment, one concentration of DA
(100µM) was chosen to induce a loss of cell viability. Further, SH-SY5Y cells were
pretreated with 5µM of resveratrol (RV1), pinostilbene (RV2), desoxyrhapontigenin
(RV3), pterostilbene (RV4), pterostilbene glucoside (RV5), resveratrol trimethylether
(RV6), picetannol (RV7), or piceid (RV8) to determine if any of these compounds could
prevent

DA-induced

cell

death.

Resveratrol

(RV1),

pinostilbene

(RV2),

desoxyrhapontigenin (RV3), and piceid (RV8) significantly inhibited DA-induced loss of
SH-SY5Y cell viability (Fig. 23).
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23

Figure 23. Resveratrol and analogs protect against DA-induced oxidative
stress.
Results are presented as mean ± SEM, n = 3. Dopamine treatment (100µM; 24hr)
significantly decreased cell viability in SH-SY5Y cells, measured by ATP
luminescence. Pretreatment (30 min) with 5µM of resveratrol (RV1; *p<0.05 vs
100µM DA), pinostilbene (RV2; **p<0.01 vs 100µM DA), desoxyrhapontigenin
(RV3; *p<0.05 vs 100µM DA), or piceid (RV8; **p<0.01 vs 100µM DA)
increased cell viability after DA treatment. Data were analyzed using a two-way
ANOVA with a post hoc analysis with Fisher’s LSD test.
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12.2 Resveratrol and pinostilbene protect against DA-induced oxidative stress
In order to determine if resveratrol or pinostilbene would protect against DAinduced oxidative stress at lower concentrations, SH-SY5Y cells were pretreated with
varying concentrations of resveratrol or pinostilbene (1, 3, or 5µM) followed by DA
treatment (50, 100 or 200µM). DA treatment significantly decreased SH-SY5Y cell
viability at 50µM (85% of control) and 100µM (57% of control; Fig. 24A, white bars) as
measured by loss of ATP luminescence. Pretreatment with resveratrol (RV1; 1, 3, or
5µM) or pinostilbene (RV2; 1, 3, or 5µM) inhibited the DA-induced loss of SH-SY5Y
cell viability (Figs. 24A and 25A).
In support of the cell viability data measured by ATP levels, treatment with DA
significantly decreased the amount of live cells (24B and 25B). However, resveratrol
pretreatment (1µM) preserved SH-SY5Y cell nuclear integrity, as measured by Hoechst
staining, following 50 and 100µM DA exposure (Figs. 24B). However, pinostilbene
pretreatment did not protect against the DA-induced loss of nuclear integrity (Fig. 25B).
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24A

24B

Figure 24. Resveratrol protects against DA-induced oxidative stress.
Results are presented as mean ± SEM, n = 3. (A) DA significantly reduced ATP
luminescence in SH-SY5Y cells (^p<0.05, ^^p<.01 vs H2O control). Pretreatment
(30min) with resveratrol (RV1; 1-5µM) protected against loss of ATP luminescence
at 100 and 200µM DA. (B) DA treatment significantly decreased the average number
of intact nuclei as measured by Hoechst stain (^p<0.05 vs H2O control). Pretreatment
with resveratrol (1µM) protected nuclear viability from DA-induced oxidative
damage (100µM; *p<0.05). Data were analyzed using a two-way ANOVA with a
post hoc analysis with Fisher’s LSD test.
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25A

25B

Figure 25. Pinostilbene protects SH-SY5Y cells from DA-induced oxidative
stress.
Results are presented as mean ± SEM, n = 3. (A) DA significantly reduced ATP
luminescence in SH-SY5Y cells (^p<0.05, ^^p<0.01 vs H2O control). Pretreatment
(30min) with pinostilbene (RV2; 1-5µM) protected against loss of ATP luminescence
at 100µM DA (*p<0.05, **p<0.01, **p<0.001 vs 100µM DA). (B) DA treatment
significantly decreased the average number of intact nuclei as measured by Hoechst
stain (^p<0.001 vs H2O control). Pretreatment with pinostilbene did not protect
nuclear viability from DA-induced oxidative damage. Data were analyzed using a
two-way ANOVA with a post hoc analysis with Fisher’s LSD test.
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12.3 Resveratrol treatment increases ERK1/2 activation in SH-SY5Y cells
To assess whether resveratrol or pinostilbene treatment could activate the MAP
kinases, ERK1/2 or ERK5, SH-SY5Y cells were treated with 5µM or resveratrol (RV1)
or pinostilbene (RV2) over a time course (5min-48hr). Resveratrol treatment (5µM)
transiently increased ERK1/2 and 5 activation in SH-SY5Y cells, such that activation was
returned to basal levels by 24 hr (Fig. 26A, B, and C). In contrast to resveratrol treatment,
pinostilbene treatment (5µM) increased activation of ERK1 and ERK2 by 15 min and
was sustained through 48 hr (Fig. 27B). Due to on the large variability in the
phosphorylation of ERK5 following pinostilbene treatement, it was unclear whether there
was any significant activation of ERK5 by pinostilbene in these cells (Fig. 27C).
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Figure 26. Resveratrol treatment activates ERK1/2 in a time-dependent manner.
Results are presented as mean ± SEM. n = 3 SH-SY5Y cells were treated with resveratrol
(5µM) over a time course and assessed for ERK1/2 and ERK5 activation. Resveratrol
treatment increased pERK1 (A) and pERK2 (B) in a time-dependent manner (*p<0.05 vs
no treatment; NT). ERK5 (C) was not activated by resveratrol treatment. Data were
analyzed using a one-way ANOVA with a post hoc analysis with Fisher’s LSD test.
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27A

27B

27C

Figure 27. Pinostilbene treatment activates ERK1 and ERK2 in a time-dependent
manner.
Results are presented as mean ± SEM. n = 3 SH-SY5Y cells were treated with
pinostilbene (5µM) over a time course and assessed for ERK1/2 and ERK5 activation.
Pinostilbene treatment increased pERK1 (A) and pERK2 (B) in a time-dependent
manner. ERK5 (C) was not activated by pinostilbene treatment. Data were analyzed
using a one-way ANOVA with a post hoc analysis with Fisher’s LSD test
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12.4 U0126 treatment blocks ERK1/2 activation in SH-SH5Y cells
To assess the specificity of the ERK1/2 inhibitor, U0126, in SH-SY5Y cultures,
cells were treated with 10, 30 or 50µM for 1hr. All doses of U0126 blocked basal
ERK1/2 activation (Fig. 28). From these results 10µM U0126 was chosen for further
studies. SH-SY5Y cells were then treated over a time course with 10µM U0126 and
analyzed by Western blot. U0126 (10µM) effectively blocked ERK1/2 activation for 24
hr (Fig. 29). ERK5 expression and activation was also analyzed to determine the
specificity of U0126. Basal ERK5 activation was unaffected by 10µM U0126 treatment
in SH-SY5Y cells (Fig. 29).
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Figure 28. U0126 treatment inhibits ERK1/2 activation in SH-SY5Y cells.
Results are presented as mean ± SEM. n = 3 SH-SY5Y cells were treated with
pinostilbene (5µM) over a time course and assessed for ERK1/2 and ERK5 activation.
Pinostilbene treatment increased pERK1 (A) and pERK2 (B) in a time-dependent
manner. ERK5 (C) was not activated by pinostilbene treatment. Data were analyzed
using a one-way ANOVA with a post hoc analysis with Fisher’s LSD test
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Figure 29. U0126 treatment inhibits prolonged ERK1/2 activation in SH-SY5Y
cells.
Results are presented as mean ± SEM. n = 3 SH-SY5Y cells were treated with U0126
(10µM) over a time course and assessed for ERK1/2 activation. Ttreatment with
U0126 decreased pERK1 (A) and pERK2 (B) in a time-dependent manner and was
sustained for 24hr. Total protein levels of ERK1 and ERK2 were unaffected by U0126
treatment. Western blot was performed by Mayur Parmar.
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12.5 Treatment with U0126 blocks resveratrol activation of ERK1/2
In order to assess whether resveratrol or pinostilbene treatment would increase
phosphorylation (activation) of ERK1 and ERK2, SH-SY5Y cells were treated with 5µM
of resveratrol or pinostilbene for 30min. Cells were then lysed and assessed for activation
of ERK1/2 by Western blot analysis. Resveratrol and pinostilbene treatment (5µM)
increased ERK1 and ERK2 activation. Further, SH-SY5Y cells were treated with U0126
(10µM) prior to treatment with resveratrol or pinostilbene to determine if resveratrol or
pinostilbene activation of ERK1/2 would be inhibited. Resveratrol and pinostilbene
activation of ERK1 and ERK2 was significantly decreased by pretreatment with 10µM
U0126 (Fig. 30A/B and 31A/B, respectively). Analysis of ERK5 expression showed no
change in activation after treatment with resveratrol, pinostilbene, and/or U0126 (Fig.
30C and 31C).
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Figure 30. Resveratrol mediated activation of ERK1/2 is inhibited by U0126
treatment in SH-SY5Y cells.
Results are presented as mean ± SEM, n = 3. (A) Resveratrol treatment (1µM)
increases pERK1 (*p<0.05). U0126 (10µM) inhibits resveratrol mediated activation
of ERK1 (*p<0.05). (B) Resveratrol treatment increases PERK2 and U0126 inhibits
this activation of ERK2 (*p<0.05). ERK5 is not activated by resveratrol treatment and
is unaffected by U0126 treatment. Data were analyzed using a two-way ANOVA with
a post hoc analysis with Fisher’s LSD test.
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Figure 31. Pinostilbene mediated activation of ERK1/2 is inhibited by U0126
pretreatment in SH-SY5Y cells.
Results are presented as mean ± SEM, n = 3. (A) Pinostilbene treatment (1µM)
increases pERK1. U0126 (10µM) inhibits pinostilbene mediated activation of ERK1
(**p<0.01) and decreases basal activation of ERK1 (*p<.05). (B) Pinostilbene
treatment increases PERK2 and U0126 inhibits this activation of ERK2 (*p<0.05).
ERK5 is not activated by resveratrol treatment and is unaffected by U0126 treatment.
Data were analyzed using a two-way ANOVA with a post hoc analysis with Fisher’s
LSD test.
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12.6 Resveratrol - mediated protection from DA-induced oxidative stress in SHSY5Y cells is blocked by U0126 pretreatment
To examine the role of ERK1/2 activation in resveratrol-mediated protection from
DA-induced oxidative stress, SH-SY5Y cells were pretreated with 10µM U0126 prior to
resveratrol (1, 3, and 5µM) and dopamine (100µM) treatments. In agreement with earlier
data, 100µM DA treatment significantly decreased cell viability and pretreatment with
resveratrol (1, 3, and 5µM) increased cell viability as measured by an increase in ATP
luminescence (32A). Pretreatment with 10µM U0126 blocked this resveratrol-mediated
protection at all three concentrations (32A; 1, 3, and 5µM).
Corroborating the data from the ATP viability assays, treatment with 100µM DA
decreased SH-SY5Y cell viability by 40% as measured by Hoechst staining. Treatment
with resveratrol (1µM) significantly increased cell viability as measured by counting live
cells (Fig. 32B). Pretreatment with U0126 (10µM) inhibited resveratrol-mediated
protection (32B).
Similarly, pinostilbene treatment (1, 3, and 5µM) increased cell viability after
exposure to DA (100µM), as measured by ATP luminescence (33A). Pretreatment with
U0126 (10µM) blocked pinostilbene-mediated protection of cell viability.
In agreement with the Cell Titer Glo data, treatment with 100µM dopamine
significantly decreased nuclear integrity as measured by Hoechst stained nuclei (33B).
Surprisingly, pinostilbene treatment (1, 3, or 5µM) did not protect SH-SY5Y cells from
dopamine (100µM) - induced oxidative stress (Fig. 33B).
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Figure 32. Resveratrol mediated protection from DA-induced oxidative stress is
inhibited by U0126.
Results are presented as mean ± SEM, n = 3. (A) DA significantly reduced ATP
luminescence in SH-SY5Y cells (^p<0.05 vs H2O control). Pretreatment (30min) with
resveratrol (RV1; 1-5µM) protected against loss of ATP luminescence at 100µM DA
(**p<0.01, **p<0.001 vs 100µM DA). Pretreatment with U0126 (1hr; 10µM) blocked
resveratrol-mediated protection. (B) DA treatment significantly decreased the average
number of intact nuclei as measured by Hoechst stain (^p<0.001 vs H2O control).
Pretreatment with resveratrol (1µM) protected nuclear viability from DA-induced
oxidative damage (*p<0.05 vs 100µM). Pretreatment with U0126 blocked resveratrolmediated protection. Data were analyzed using a two-way ANOVA with a post hoc
analysis with Fisher’s LSD test.
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Figure 33. Pinostilbene mediated protection from DA-induced oxidative stress is
inhibited by U0126.
Results are presented as mean ± SEM, n = 3. (A) DA significantly reduced ATP
luminescence in SH-SY5Y cells (^p<0.05 and ^^p<0.01 vs H2O control). Pretreatment
(30min) with pinostilbene (RV2; 1-5µM) protected against loss of ATP luminescence
at 100µM DA (*p<0.05, **p<0.01, **p<0.001 vs 100µM DA). Pretreatment with
U0126 (1hr; 10µM) blocked pinostilbene-mediated protection. (B) DA treatment
significantly decreased the average number of intact nuclei as measured by Hoechst
stain (****p<0.0001 vs H2O control). Pretreatment with pinostilbene did not protect
nuclear viability from DA-induced oxidative damage. Data were analyzed using a
two-way ANOVA with a post hoc analysis with Fisher’s LSD test.
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12.7 Preparation of wild blueberry powder affected SH-SY5Y cell viability
To assess whether wild blueberry powder would protect against DA-induced
oxidative stress, SH-SY5Y cells were pretreated with two concentrations of dissolved
WBB (250 and 500µg/mL) followed by treatment with DA (50, 100, and 200µM). DA
treatment (100 and 200µM) significantly decreased cell viability, as measured by ATP
luminescence (**p<0.01 and ***p<0.001, respectively). Wild blueberry powder did not
show protection from DA-induced oxidative stress (Fig 34), however this may be due to
our inability to fully dissolve the wild blueberry powder, despite several attempts using
protocols that were successful in other laboratories (communications with Dr. Barbara
Shukitt-Hale and Derek Fisher). The powder was suspended in serum-free media and
incubated at 37°C for 15 min. The suspension was briefly sonicated and vortexed. After
the suspension looked fully mixed by eye, it was centrifuged for 5 min at 2000rpm. The
supernatant was then used to treat SH-SY5Y cells. Non-soluble particles were still left at
the bottom of the centrifuge tube. Some particles remained in the supernatant, which may
have affected cell viability.
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34

Figure 34. Wild blueberry powder does not protect against DA-induced
oxidative stress.
Results are presented as mean ± SEM, n = 3. DA significantly reduced ATP
luminescence in SH-SY5Y cells (**p<0.01, ***p<0.001 vs H2O control).
Pretreatment (30min) with wild blueberry powder (WBB) did not protect against loss
of ATP luminescence by DA-induced oxidative stress. Data were analyzed using a
two-way ANOVA with a post hoc analysis with Fisher’s LSD test.
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13. DISCUSSION
In the current study, SH-SY5Y cells were used as a model of DA neurons to test
the protective effect of the isolated natural compounds, resveratrol and pinostilbene,
against oxidative stress. DA, which is an endogenous neurotransmitter, was used as a
toxin that produces ROS. DA increased SH-SY5Y cell death in a concentration
dependent manner. Initially a multitude of compounds, including resveratrol (see page
14) were used to determine which would protect against DA-induced oxidative stress.
Two compounds that were chosen to move forward with were resveratrol (RV1) and
pinostilbene (RV2) as they both showed significant protection against DA-induced
oxidative stress. Further, pretreatment with even lowere concentrations of resveratrol and
pinostilbene (1-5µM) protected against DA-induced cell death. Resveratrol and
pinostilbene activated ERK1/2 in these cells and the ERK1/2 inhibitor, U0126, blocked
the resveratrol and pinostilbene-mediated protection from DA toxicity. These data
suggest that resveratrol and pinostilbene protect DA neurons from oxidative stress via
activation of the ERK1/2 pathways. These are the first studies to show activation of
ERK1/2 by resveratrol and pinostilbene in DA cells and a role for these signaling
cascades in resveratrol and pinostilbene-mediated protection.
Decreases in DA neurons and projections have been noted with aging and, as DA
neurons are more susceptible to oxidative stress, these age-related alterations in the DA
system may occur due to an increase in ROS with age. One reason that DA neurons may
be more susceptible to oxidative stress is that DA metabolism produces reactive oxygen
species, such as oxidative radicals and DA quinones. With age, it has also been shown
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that there is a decrease in endogenous antioxidant systems, such as GSH, catalase, and
NADPH (Mo et al., 1995; Papadopoulos et al., 1998; Sasaki et al., 2001). Therefore, DA
neurons are in an environment high in ROS with reduced antioxidant systems that could
lead to increased vulnerability. This increase in oxidative stress in the brain with aging
has been shown to be either contributing to or be caused by several neurodegenerative
diseases (Junqueira et al., 2004; Wang and Michaelis, 2010). With respect to age-related
motor decline and DA neurodegeneration, oxidative stress has been shown to increase
with age and to be toxic to DA neurons (Joseph et al., 1999). It follows that
administration of antioxidants, such as those found in natural products, would be a viable
treatment for age-related increases in oxidative stress.
Many dietary products have been shown to exhibit antioxidant properties, such as
green tea, red wine, grapes, and blueberries. Additionally, some isolated compounds from
these natural products have been shown to have anticancer, anti-inflammatory,
cardioprotective and neuroprotective effects. One such compound is resveratrol.
Resveratrol has been shown to have neuroprotective effects in SH-SY5Y cells that were
exposed to 6-OHDA (Chao et al., 2008; 2010). However, the exact mechanism by which
resveratrol protects from oxidative stress has not been fully elucidated. One pathway that
is activated in response to stress that is specifically of interest in this project is the MAPK
pathway, in particular ERK1/2.
ERK1/2 has been shown to be important for neuronal differentiation,
proliferation, and cell fate (Nishimoto and Nishida, 2006; Krishna and Narang, 2008;
Van Kolen et al., 2013). During embryonic development, ERK1/2 has been shown to be
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particularly important and knockout models of ERK2 are embryonic lethal, possibly due
to a retardation of growth of the placenta and heart of the embryos (Hatano et al., 2003).
However, ERK1 knockout models are not embryonic lethal, indicating that ERK1 and
ERK2 do have individual roles in embryonic development (Samuels et al., 2009).
ERK1/2 deficiencies are also associated with mental retardation, indicating an
importance in the regulation of neural progenitor cells (Samuels et al., 2009).
Another important role of the MAPK pathways, particularly ERK1/2, is activation
in response to cellular stress, such as ROS. H2O2-induced ERK1/2 activation is thought to
play a critical role in cell survival in response to oxidative stress in rat PC12 cells and
primary cortical neurons (Guyton et al., 1996; Crossthwaite et al., 2002). ERK1/2
activation was also shown to protect against hypoxia-induced cell death (Wang et al.,
2001). However, some studies indicated the ERK1/2 activation plays a role in apoptosis
associated with oxidative stress (Ruffels et al., 2004). Therefore, this study investigated
the role of ERK1/2 in a model of DA-induced oxidative stress to determine whether
resveratrol-mediated protection of SH-SY5Y cells was via ERK1/2 activation.
Treatment with resveratrol (5µM) increased both ERK1 and ERK2 activity in a
time-dependent manner (Fig. 26). ERK5 was also transiently activated following
resveratrol treatment. Without further investigation these studies could not definitively
determine whether resveratrol-mediated protection against DA-induced oxidative stress
was due to ERK1/2 activation. Magliaro and Saldanha (2009) found the use of U0126,
the ERK1/2 specific inhibitor, protected PC-12 cells from H2O2-induced cell death;
however Gomez-Santos and colleagues (2002) found that activation of ERK1/2 protected
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SH-SY5Y cells from MPP+ toxicity. Therefore, the ERK1/2 specific inhibitor, U0126,
was used to block ERK1/2 activation. Treatment with resveratrol (1µM) increased both
ERK1 and ERK2 activation, which was subsequently blocked by pretreatment with
U0126 (10µM; Fig. 30). ERK5 was not activated with resveratrol treatment and pretreatment with U0126 did not alter ERK5 expression or activation.
Since, U0126 effectively inhibited resveratrol-mediated activation of ERK1 and
ERK2; U0126 was used to examine the role of ERK1/2 in resveratrol-mediated
protection against oxidative stress. SH-SY5Y cells treated with 100µM DA showed a
significant decrease in cell viability, as measured by ATP luminescence. Pre-treatment
with resveratrol (1, 3, and 5µM) increased cell viability significantly against DA-induced
oxidative stress (Fig. 32). Further, treatment with U0126 prior to administration of
resveratrol showed a reduction in cell viability as measured by ATP luminescence and
nuclear integrity. These data suggest that resveratrol-mediated protection of SH-SY5Y
cells is due to the activation of ERK1/2. In agreement with this data, Gu and colleagues
(2013) found that propofol, an anesthetic agent, protected SH-SY5Y cells from H2O2induced oxidative stress via ERK1/2 activation.
As stated previously, resveratrol has low bioactivity due to rapid metabolism into
glucoronides and sulfate conjugates (Marier et al., 2002; Goldberg et al., 2003).
Methylation of the hydroxyl groups of resveratrol has been shown to increase bioactivity,
through prolonged bioavailability and increased permeability of the cell membrane (Chao
et al., 2010). Therefore, this study sought to investigate the role of a resveratrol analog,
pinostilbene, in the protection of SH-SY5Y cells from DA-induced cell death.
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Similar to the resveratrol study, DA was used to induce oxidative stress.
Increasing concentrations of DA reduced cell viability significantly in SH-SY5Y cells as
measured by ATP luminescence and nuclear integrity. Pretreatment with pinostilbene (1,
3, and 5µM) protected against DA-induced oxidative stress, as measured by ATP
luminescence (Fig. 25A). However, pinostilbene treatment did not protect against DAinduced loss of nuclear integrity as measured by Hoechst staining (25B). Chao and
colleagues (2010) showed that pinostilbene decreased activation of JNK-1, JNK-2, and cjun-1 in SH-SY5Y. This data indicates the pinostilbene is able to modulate signaling in
the MAPK family. Therefore, further studies were done to investigate pinostilbene
activation of the ERKs.
To investigate the role of the MAPKs, ERK1/2, SH-SY5Y cells were treated with
pinostilbene (5µM). Pinostilbene transiently increased ERK1 and ERK2 activation. As
seen with the resveratrol treatment, activation of ERK5 by pinostilbene treatment is
inconclusive due to the large errors bar with ERK5 quantification (Fig. 27C). These data
may indicate that there are distinct roles for ERK1/2 versus ERK5 in cell survival.
Currently, there is limited research on pinostilbene and no studies investigating
pinostilbene and ERK1/2. Since the data of this study found that pinostilbene protected
SH-SY5Y cells from DA-induced cell death and activated ERK1/2, we wanted to
investigate the role of ERK signaling and pinostilbene-mediated protection of SH-SY5Y
cells from DA-induced cell death. Therefore, SH-SY5Y cells were treated with U0126
prior to pinostilbene (1, 3 or, 5µM) and DA (100µM) treatment. As previously seen, DA
treatment decreased cell viability by 54.6% and treatment with pinostilbene (1, 3 or,
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5µM) increased cell viability, as measured by ATP luminescence. Pretreatment with
U0126 inhibited approximately half of the cell viability increase mediated by
pinostilbene treatment (Fig. 33A). These data suggest that pinostilbene-mediated
protection of SH-SY5Y cells from oxidative stress may be modulated by ERK1/2
activation.
Joseph and colleagues (2010) have shown that treatment with wild blueberry
powder attenuates Ca2+ signaling in primary hippocampal neurons, leading to cell
survival. Therefore, the role of WBB in SH-SY5Y cells and oxidative stress was
investigated in the current study. In this model, DA effectively decreased cell viability, as
measured by ATP luminescence (Fig. 34). However, treatment with wild blueberry
(WBB) powder did not protect against DA-induced oxidative stress (Fig. 34). The lack of
protection may be due to the incomplete dissolution of the WBBs. After the SH-SY5Y
cells were treated with the suspended WBBs, they were observed under a light
microscope. There were distinct particles observed in the media that may have been
insoluble fractions of the WBB powder. Therefore, the dissolution of the WBB may have
been incomplete. Different techniques to dissolve WBB powder were discussed with the
Joseph lab and, even with their guidance, WBB powder was not successfully dissolved.
Non-soluble particles still remained in the solution, even after sonication, centrifugation,
and filtration with a 0.45µm syringe filter. This solubility issue with the WBB powder
may be why there was not protection with the WBB solution.
In conclusion, resveratrol and pinostilbene protected SH-SY5Y cells from DAinduced oxidative stress. This data suggests that activation of the ERK1/2 signaling
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cascades may be involved due to a reduction in cell viability with the use of the ERK1/2
specific inhibitor, U0126. As these natural supplements are widely used, it is important to
understand the mechanism by which they provide neuroprotection so as to avoid
unwanted side effects and/or drug – drug interactions. Furthermore, elucidation of the
mechanism of action of these compounds will allow for future design of compounds that
target these same signaling pathways.
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14. CONCLUSION
The aging population is increasing at a significant rate. There is a lack of treatments
for age-related motor deficits. While L-DOPA effectively reversed age-related motor deficits,
long-term treatment can cause dyskinesias. Therefore, there is a need for an effective
treatment for motor deficits. Our study showed that natural products may fill this need.
In the present study, we found that L-DOPA, wild blueberries - and resveratrol –
supplemented diets attenuated age-related motor deficits in an aging mouse model. We did
not find any changes in the DA system with age, however wild blueberries increased the
amount of TH+ neurons in the SN. These data indicate that natural products, such as wild
blueberries may be effective at reversing age-related motor deficits.
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16. SUPPLEMENTAL FIGURES

Supplemental Figure 1. U0126 (1,4-diamino-2,3-dicyano-1,4-bis[2aminophenylthio]butadiene)

Supplemental Figure 2. PD98059 (2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran4-one)
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Supplemental Figure 3. XMD 8-92 (2-[[2-Ethoxy-4-(4-hydroxy-1piperidinyl)phenyl]amino]-5,11-dihydro-5,11-dimethyl-6H-pyrimido[4,5b][1,4]benzodiazepine-6-one
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Supplemental Figure 4. BIX02189 (3-[[[3[dimethylamino)methyl]phenyl]amino]phenylmethylene]-2,3-dihydro-N,N-dimethyl2-oxo-1H-indole-6-carboxamide)
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